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Abstract 
 
 
Rationale: Following repeated +/-3,4-methylenedioxymethamphetamine 
(MDMA) administration there is tolerance to many behavioural effects and deficits in 
serotonergic neurotransmission.  
Objectives: The present studies had three main objectives. 1. To develop a 
behavioural assay to examine the effects of acute and repeated MDMA exposure. 2. 
To use this behavioural assay to determine whether functional changes in serotonin 
(5-HT)2a or 5-HT2c receptors accompany tolerance to the effects of MDMA. 3. To 
attempt to reverse behavioural tolerance and 5-HT deficits by administering a 
treatment that has been shown to desensitise the 5-HT1a autoreceptor. 
Methods: In separate groups of rats the dose effect curves for MDMA-
produced hyperactivity were determined (0.0, 1.0, 3.3, 10.0 mg/kg). In additional 
groups the effect of MDMA pretreatment (4 X 10mg/kg MDMA injections at 2 hour 
intervals) or saline vehicle on MDMA-produced hyperactivity was assessed. To 
determine the experimental parameters for MDMA effects in the Emergence Test (ET) 
separate groups of rats received MDMA (0.0, 3.3 mg/kg) and were either habituated 
to a hide box for various periods (15, 30, 45mins) or exposed to the test arena 3 times 
over a period of days (day 1, 5, 9) or injected daily in the home cage with MDMA 
(0.0, 3.3mg/kg) for 3 days. Emergence latency following injections of MDMA (0.0, 
3.3mg/kg), the 5-HT2a /c agonist m-CPP (0.0, 0.3, 0.6 or 1.25 m/kg), the 5-HT 
releasing stimulant, fenfluramine (0.0, 1.0, 2.0 mg/kg), and the 5-HT2a agonist DOI 
(0.0, 1.0, 2.0 mg/kg) was measured. The role of 5-HT2c receptors was assessed by 
determining the effect of the 5-HT2c antagonist, RS102221 (0.0, 0.25, 0.5, 1.0 mg/kg). 
The effect of MDMA pretreatment on MDMA (0.0, 3.3 mg/kg), m-CPP (1.25 mg/kg), 
or fenfluramine (2.0mg/kg) induced increases in emergence latency was also assessed. 
The functional status of the 5-HT1a autoreceptor following MDMA 
pretreatment was determined by measuring the effect of the 5-HT1a agonist, 8-
OHDPAT (0.0, 0.315, 0.0625, 0.125, 0.25, 0.5 mg/kg, SC), on body temperature. The 
ability of the 5-HT1a antagonist, WAY100635 (0.0, 0.01, 0.1, 1.0mg/kg, SC, 1 X daily 
for 7 days or by local injection of 0.0 or 500 ng into the dorsal raphe) to reverse the 
attenuation of MDMA-induced hyperactivity following MDMA pretreatment was 
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examined. Effects of various treatments on tissue levels of 5-HT and 5-HIAA were 
also measured using HPLC with EC. Results: MDMA produced dose-dependent 
hyperactivity and tolerance was produced by MDMA pretreatment. MDMA 
(3.3mg/kg) increased emergence latency following a 30 minute habituation period and 
this effect was reduced in MDMA-pretreated rats. Fenfluramine and m-CPP but not 
DOI also increased emergence latency in a dose-dependent manner. RS102221 dose 
dependently blocked the acute effects of MDMA and m-CPP. Two weeks following 
MDMA pretreatment rats were tolerant to the effects of MDMA and fenfluramine, but 
not m-CPP. MDMA pretreatment also produced significant reductions in tissue levels 
of 5-HT and 5-HIAA.  
Subcutaneous WAY100635 administration failed to reverse the behavioural 
and neurochemical deficits produced by MDMA pretreatment but local administration 
increased MDMA-produced hyperactivity in saline and MDMA pretreated rats and 
reversed MDMA-produced 5-HT tissue depletions.  
Conclusion: The Emergence Test is a behavioural assay sensitive to the effects 
of acute and repeated MDMA exposure. Following MDMA pretreatment behavioural 
tolerance as measured by the ET is likely to be due to impaired 5-HT release rather 
than changes in 5-HT2a or 5-HT2c receptor responses. Because partial reversal of 
tolerance and 5-HT deficits following repeated MDMA administration was achieved 
through local DRN 5-HT1a antagonist administration the 5-HT1a autoreceptor may 
prove to be a clinical target for the reversal of MDMA produced deficits.
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Introduction 
MDMA “Ecstasy”  
Brief History 
3,4-Methylenedioxymethamphetamine (MDMA) is a ring substituted 
amphetamine derivative structurally related to the stimulant methamphetamine and 
the hallucinogen mescaline (Green, Cross, & Goodwin, 1995; White, Obradovic, 
Imel, & Wheaton, 1996). MDMA’s unique psychoactive effects, which include 
stimulant and hallucinogenic actions, coupled with an ability to produce subjective 
effects such as empathy and interpersonal understanding has made MDMA an 
increasingly popular recreational drug of choice (Nichols & Oberlender, 1990; 
Parrott, 2001). 
  
First patented in 1914 by Merck Pharmaceuticals (Lyles & Cadet, 2003) 
MDMA remained largely unstudied until the early 1970s. In 1977, due to its lack of 
therapeutic efficacy, the United Kingdom scheduled MDMA as a Class A drug. In 
the Unites States, however, it had become a popular psychotherapeutic tool 
sometimes known as “penicillin for the soul” (Parrott, 2001). Following an increase 
in the prevalence of its abuse, and evidence of adverse physiological and 
psychological effects, MDMA was placed on the list of Schedule 1 drugs by the U.S. 
Drug Enforcement Administration (DEA) in 1985 (Cole & Sumnall, 2003a). 
 
 Despite MDMA’s illegal status it continues to be a popular drug likely due to 
its subjective affects which include feelings of euphoria, increased energy and 
sensory and sexual pleasure. However, it is MDMA’s adverse effects that have 
prompted ongoing research into its short and long term effects (Cohen, 1995; Liechti, 
Baumann, Gamma, & Vollenweider, 2000a; Parrott, 2002; Peroutka, Newman, & 
Harris, 1988; Verheyden, Henry, & Curran, 2003; Vollenweider, Gamma, Liechti, & 
Huber, 1998).  
Epidemiology and Patterns of Use 
There is substantial evidence that global MDMA consumption, manufacture 
and trafficking has increased over the past decade (United Nations Office on Drugs 
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and Crime, 2004). In the early 1990’s MDMA trafficking was almost exclusively 
restricted to Europe however, by 2002, MDMA use had spread worldwide. The 
highest levels of MDMA use were found in the Oceania region with Australia and 
New Zealand reporting increases in trafficking and consumption above the global 
average. Recent reports indicate that, in contrast to other drugs such as cocaine and 
cannabis, MDMA use in New Zealand continues to increase. In 2006, the New 
Zealand National Household survey data found that the population prevalence of 
MDMA consumption increased compared to 2004 (7.5% versus 5.2%) (SHORE, 
2006). 
MDMA use originally centred around parties often held at large dance clubs 
over weekends (Cole & Sumnall, 2003a). However, studies indicated a trend towards 
more widespread use across increasingly diverse populations and situations (Wilkins, 
Bhatta, Pledger, & Casswell, 2003; Wilkins, Sweetsur, & Casswell, 2006). Distinct 
patterns of MDMA use have been reported with increased MDMA experience 
associated with both increases in dose and frequency of use (Fox, Parrott, & Turner, 
2001; Parrott, 2002; Scholey et al., 2004; Verheyden et al., 2003; Verkes et al., 
2001). Novice users (1-9 lifetime occasions) reported consuming on average 1.2 
tablets per session while moderate users (10-99 occasions) increased the dose to 1.8 
tablets (Scholey et al., 2004; Verheyden et al., 2003). Heavy users, those who taken 
MDMA on more than 100 occasions, reported a mean of 3.7 tablets per occasion 
with 35% indicating a maximum average of 10.7 tablets (Scholey et al., 2004). 
Additionally, patterns of binging were reported in heavy MDMA users with over one 
third reported to binge over a 48hr period on a regular basis (Parrott, 2005; Topp, 
Hando, Dillon, Roche, & Solowij, 1999). The increase in MDMA dose and 
frequency of use has been associated with the development of tolerance. Tolerance 
can be defined as a progressively decreasing response to a drug (Merrill, 1996; 
Parrott, Milani, Parmar, & Turner, 2001; Peroutka et al., 1988; Scholey et al., 2004). 
A study revealed that DSM criteria for abuse and dependence were met by 25% of 
the sample with the most commonly reported criteria being the development of 
tolerance (65%) (EACD, 2004) Additionally, animal studies have shown that, 
compared to other drugs of addiction, maintenance of MDMA self-administration is 
facilitated by prolonged exposure to, and higher doses of, MDMA (Schenk et al., 
2007). 
  
10 
Effects of MDMA Use 
As MDMA use has increased so have the reports of serious adverse 
physiological and psychological effects.  Acute MDMA has been associated with 
hypertension, hyperthermia and cardiac arrhythmias as well as transient depression 
and anxiety (Parrott, 2002; Vollenweider et al., 1998). 
Evidence indicates that long term and heavy MDMA use is associated with 
insomnia, energy loss, irritability, persistent cognitive impairments and mood 
disturbances (Dalley et al., 2007; Fox et al., 2001; Morgan, 2000; Parrott, 2002; 
Reneman, Booij, Majoie, Van Den Brink, & Den Heeten, 2001; Topp et al., 1999; 
Verheyden et al., 2003; Verkes et al., 2001).  
There are numerous studies showing that MDMA exposure produces major 
changes to brain neurochemical systems that may be persistent (Green, Mechan, 
Elliott, O'Shea, & Colado, 2003). Furthermore, some studies indicate that MDMA 
can produce neurotoxicity (O'Hearn, Battaglia, De Souza, Kuhar, & Molliver 1988; 
Schmidt, 1987; Steele, McCann, & Ricaurte, 1994). These neurochemical changes 
may underlie the cognitive and behavioural deficits reported by MDMA users (Cole 
& Sumnall, 2003a; Liechti et al., 2000a; Liechti, Saur, Gamma, Hell, & 
Vollenweider, 2000b; Verheyden et al., 2003).  
 
Pharmacokinetics of MDMA    
MDMA contains a racemic mixture of (+) and (-) isomers each different in 
their metabolism, elimination and effects on neurotransmitter release. The (+) isomer 
is metabolised and cleared faster (Fallon et al., 1999; Fitzgerald & Reid, 1990), is a 
more potent releaser of  neurotransmitters and, in particular, is a more effective 
dopamine (DA) releaser than the (-) isomer (Johnson, Hoffman, & Nichols, 1986). 
The MDMA isomers also vary in contribution to changes in the 5-HT function and 
neurotoxicity (Johnson et al., 1986).When compared to other amphetamines MDMA 
is a potent 5-HT releaser. For example, (+)-MDMA-induced 5-HT release is ten 
times greater than (+)-methamphetamine (White et al., 1996). It is these 
neurochemical differences that make MDMA a distinctive drug in its subjective and 
neurochemical effects. 
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“Ecstasy” tablets most commonly ingested contain a racemic mixture of (+) 
and (-) isomers of MDMA. MDMA serum levels are detectable within 15 minutes 
and reach peak concentration about 2 hours after oral ingestion. MDMA is 
metabolised mainly in the liver by the enzyme, CYP2D6. However, other enzymes 
are also involved some of which become saturated at relatively low concentrations of 
the drug. Therefore, as the dose is increased, disproportionately large increases in 
plasma and brain concentrations occur. Consequently, small increases in dosage may 
markedly increase the risk of neurotoxicity especially in heavy MDMA users (de la 
Torre et al., 2000a). Elimination of MDMA from the body is relatively slow with a 
half life of approximately 8 hours in humans (de la Torre et al., 2000b; Mas et al., 
1999).  
Pharmacology and Mechanisms of MDMA   
MDMA initially produces a rapid increase in extracellular levels of serotonin 
(5-HT), dopamine (DA), and norepinephrine (NE) with predominant effects on 5-HT 
(Green et al., 2003; Gudelsky & Nash, 1996; Lyles & Cadet, 2003; Yamamoto, 
Nash, & Gudelsky, 1995). MDMA interacts with the 5-HT transporter (SERT) 
blocking 5-HT reuptake and inducing a calcium–independent carrier mediated 5-HT 
release (Gudelsky & Nash, 1996; Johnson, Conarty, & Nichols, 1991; White et al., 
1996). Additionally, MDMA directly depletes vesicular 5-HT (Mlinar & Corradetti, 
2003) and disrupts vesicle repackaging of cytosolic 5-HT (Rudnick & Wall, 1992).  
MDMA also increases synaptic levels of 5-HT by inhibiting monoamine 
oxidase (MAO) activity leading to a reduction in metabolic breakdown. Conversely, 
MDMA inhibits tryptophan hydroxylase, the rate limiting enzyme for 5-HT 
synthesis, resulting in a reduction of 5-HT availability (Schmidt, 1987; Stone, 
Johnson, Hanson, & Gibb, 1989b; Stone, Stahl, Hanson, & Gibb, 1986). 
MDMA has affinity for a range of pre and postsynaptic 5-HT receptors 
(Battaglia, Brooks, Kulsakdinun, & De Souza, 1988). Activation of the 5-HT 
receptors following MDMA administration is thought to underlie many of the 
subjective, neurochemical and behavioural responses following MDMA use 
including hyperactivity(Callaway, Rempel, Peng, & Geyer, 1992; Fletcher, Korth, 
Robinson, & Baker, 2002; Kehne et al., 1996), hyperthermia (Aguirre, Ballaz, 
Lasheras, & Del Rio, 1998; Dafters, 1994; Green et al., 2004) and exploratory 
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behaviour (Bull, Hutson, & Fone, 2004; McGregor et al., 2003; Sumnall, O'Shea, 
Marsden, & Cole, 2004).  
MDMA acts preferentially at the SERT with a lesser affinity at the 
norepinephrine (NE) and dopamine transporters (DAT) (Shankaran & Gudelsky, 
1999; White, Duffy, & Kalivas, 1994). MDMA is a substrate releaser, which is 
transported into the nerve terminals and causes a rapid release of serotonin via a 
reverse transport mediated and vesicle dependant mechanism (Howell & Kimmel, 
2008; Seiden et al., 1993). MDMA interacts to a lesser extent with the DA system 
increasing synaptic levels directly via DAT inhibition and indirectly via 5-HT release 
and activation of 5-HT receptors (Cole & Sumnall, 2003b; Gudelsky, Yamamoto, & 
Nash, 1994; Rudnick & Wall, 1992; White et al., 1996). The interactions between 5-
HT and DA are complex, dependent on the brain region and on the state of DA 
activity (Meltzer & Nash, 1991). DA has been shown to be an important contributor 
to MDMA-induced behaviours, however, MDMA’s ability to evoke significant 5-HT 
release due to its affinity for the SERT, and to indirectly stimulate 5-HT receptors, 
have been shown to be important components of its ability to increase DA 
neurotransmission. 
Effects of MDMA on Humans  
Acute MDMA effects in Humans 
There is extensive research outlining the physiological and psychological 
effects following acute MDMA ingestion. At recreational doses MDMA produces 
acute sympathomimetic effects such as increase in blood pressure and heart rate, 
increased activation of the hypothalamic pituitary adrenal axis and changes in 
cerebral blood flow (Gamma, Buck, Berthold, Liechti, & Vollenweider, 2000; Green 
et al., 2003; Lester et al., 2000; Vollenweider et al., 1998). Additional aversive 
effects include jaw clenching, lack of appetite, agitation, insomnia and a lack of 
concentration (Cohen, 1995; McCann, Mertl, Eligulashvili, & Ricaurte, 1999; 
Vollenweider et al., 1998). The most commonly reported adverse physiological 
response to MDMA is hyperthermia. Core body temperatures as high as 44 º C have 
been reported usually proving fatal due to complications such as multiple organ 
failure and rhabdomyolysis (Chadwick, Curry, Linsley, Freemont, & Doran, 1991; 
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Cohen, 1995; Liechti et al., 2000b).Experimental studies in humans have attributed 
psychological effects to 5-HT function since reduced inhibition, perceptual changes 
and heightened sensory effects are all attenuated by blockade of the SERT and/or 
antagonism of 5-HT2 receptors  (Cole & Sumnall, 2003a; Liechti et al., 2000a; 
Liechti et al., 2000b; Verheyden et al., 2003).  
 
Effects of Repeated MDMA exposure in Humans  
There is evidence that repeated MDMA alters the integrity of the 5-HT 
system in humans. Imaging studies revealed decreases in some structural components 
of 5-HT neurons including a reduction of 5-HT transporter sites (McCann, Szabo, 
Scheffel, Dannals, & Ricaurte, 1998; Semple, Ebmeier, Glabus, O'Carroll, & 
Johnstone, 1999) and 5-HT2 receptor binding sites (Reneman et al., 2001; Reneman 
et al., 2002). The extent of alterations was positively correlated with past MDMA use 
with heavy or repeated MDMA users more at risk of immediate and long term 5-HT 
deficits (McCann et al., 1998). Additionally, responses in 5-HT function were 
blunted in MDMA users. For example, neuroendocrine studies showed that cortisol 
and prolactin secretion were reduced in MDMA users (Gerra et al., 1998; Price, 
Ricaurte, Krystal, & Heninger, 1989). As these responses involve the activation of 5-
HT2 receptors it suggests a reduction in sensitivity and/or binding densities of these 
receptor subtypes. 
There is evidence that repeated MDMA use results in a range of cognitive 
deficits and emotional dysregulation. A battery of neuropsychological tests revealed 
that working, short-term and long term memory were all compromised in regular and 
heavy MDMA users (Fox et al., 2001; McCann et al., 1999; McCardle, Luebbers, 
Carter, Croft, & Stough, 2004; Reneman, Booij, Schmand, van den Brink, & 
Gunning, 2000). Furthermore, heavy MDMA use was associated with more 
pronounced and long lasting performance deficits (Bolla, McCann, & Ricaurte, 1998; 
McCardle et al., 2004; Verkes et al., 2001). Cognitive/memory deficits have also 
been shown to be persistent (Fox et al., 2001; Morgan, McFie, Fleetwood, & 
Robinson, 2002). Several studies found that emotional dysregulation such as 
depression, anxiety, panic disorder, paranoia and increased impulsivity persisted long 
after drug abstinence. Again, more extensive deficits and longer persistence was 
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found in heavy MDMA users (Fox et al., 2001; Morgan et al., 2002; Parrott et al., 
2002). As many of these disorders are closely linked to 5-HT impairments (Griebel, 
1995; Pineyro & Blier, 1999) these studies indicate a relationship between the extent 
of MDMA exposure and the severity of psychological impairments with heavier use 
possibly linked to more severe and longer lasting 5-HT impairments.  
Tolerance is one of the most commonly reported effects of repeated MDMA 
use. Up to 85-90% of participants reported tolerance to the effects of MDMA 
(Merrill, 1996; Verheyden et al., 2003) with many users reporting a reduction in the 
positive effects of MDMA within the first few occasions of use (Merrill, 1996; 
Parrott & Lasky, 1998; Peroutka et al., 1988; Scholey et al., 2004; Topp et al., 1999; 
Verheyden et al., 2003). Further, many participants reported that as the positive 
effects declined the negative effects, such as paranoia, increased (Merrill, 1996; 
Solowij, Hall, & Lee, 1992).  
As a result of tolerance MDMA users often changed their pattern of drug use. 
Drug dose and frequency of consumption increased in an attempt to generate the lost 
“positive on-drug experience” (Fox et al., 2001; Scholey et al., 2004; Verheyden et 
al., 2003). Patterns of binging such as boosting (multiple tablets over an extended 
period), or stacking (multiple tablets at one time) are common in users who reported 
tolerance. Furthermore, binging was related to heavy MDMA use with experienced 
users reporting significantly more binges than light users (Parrott, 2005; Scholey et 
al., 2004). In some instances a change in the method of ingestion was reported with 
snorting or intravenous injections becoming more common (Carlson, Falck, 
McCaughan, & Siegal, 2004). These findings raise the concern that as tolerance 
develops MDMA users are more at risk of administering doses high enough to exert 
lasting change or damage to brain neurochemical systems.  
Studies have attempted to investigate the consequences of MDMA use in 
humans as the patterns of binging have both immediate and long term physiological 
effects. However, as well as ethical constraints, human studies are confounded by a 
range of factors. The patterns of MDMA use and doses consumed often rely on self 
reports and retrospective surveys. Reliability of these reports is likely to be 
compromised due MDMA’s illegal status, poor recall of doses consumed and 
functional deficits experienced following MDMA use (Parrott, 2005; Topp et al., 
1999). Furthermore, the method of consumption may alter users’ experiences. 
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MDMA is commonly taken in tablet form however alternatives included intravenous 
injection, intranasal snorting and smoking (Topp et al., 1999). It has been estimated 
that each tablet contains between 80 and 150 mg of MDMA with approximately 85-
90% of tablets seized containing MDMA as the active ingredient (Cole, Bailey, 
Sumnall, Wagstaff, & King, 2002; Parrott, 2004a). However, due to MDMA being 
illicitly manufactured, the dose and purity are known to vary greatly (Green et al., 
2003; Parrott, 2004b). Additionally, other psychoactive drugs are commonly mixed 
with MDMA including amphetamine and LSD. Forensic analysis of seized MDMA 
has found amphetamine-like substances as well as unrelated compounds (WHO, 
2001). Polydrug use in MDMA users is often reported (Scholey et al., 2004). 
Therefore, it is hard to ascertain whether any long term physiological or 
psychological impairments are due to MDMA consumption alone or are a 
consequence of the combination of drugs used. Due to these restraints the effects of 
repeated MDMA exposure and the mechanisms underlying tolerance in humans 
remain elusive. 
Animal models provide an alternative method for investigating the 
behavioural responses to, and mechanisms responsible for tolerance resulting from 
repeated MDMA exposure. These models provide the advantages of flexibility, 
precision and reproducibility which allow conclusions to be drawn with control of 
extraneous variables that human studies do not afford. 
 
MDMA effects in Animals 
Acute MDMA 
In rats acute exposure to MDMA induces a unique profile of behavioural and 
physiological responses compared to its parent derivative, amphetamine. MDMA 
induces increased forward locomotion (hyperactivity) (Callaway, Wing, & Geyer, 
1990; Colado, Murray, & Green, 1993; Ross, Herin, Frankel, Thomas, & 
Cunningham, 2006; Spanos & Yamamoto, 1989), elements of the 5-HT behavioural 
syndrome such as flattened body posture, fore-paw treading and repetitive 
movements known as stereotypy (Marston, Reid, Lawrence, Olverman, & Butcher, 
1999; Piper, Fraiman, & Meyer, 2005; Shankaran & Gudelsky, 1999; Spanos & 
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Yamamoto, 1989). Alterations in exploratory behaviours have also been reported 
following acute MDMA exposure (Ho, Pawlak, Guo, & Schwarting, 2004; Lin, 
Burden, Christie, & Johnston, 1999; Morley & McGregor, 2000; Sumnall et al., 
2004). For example, decreased exploration of the elevated plus maze (EPM) was 
found following low dose MDMA while higher doses increased exploration (Lin et 
al., 1999). Additionally, MDMA consistently induces a dose dependent increase in 
body temperature (Baumann, Clark, Franken, Rutter, & Rothman, 2008; Dafters, 
1995; Mechan, O'Shea, Elliott, Colado, & Green, 2001; Shankaran & Gudelsky, 
1999).  
Repeated MDMA Exposure  
Under some circumstances tolerance following repeated MDMA exposure 
has been demonstrated. Repeated high dose MDMA administered in a single day (4x 
2hrly 10mg/kg) reduced MDMA-induced hyperactivity, components of the MDMA-
induced 5-HT syndrome, and MDMA-produced hyperthermia (Brennan & Schenk, 
2006; Callaway & Geyer, 1992; Piper & Meyer, 2006; Shankaran & Gudelsky, 1999; 
Slikker et al., 1989; Wallace, Gudelsky, & Vorhees, 2001). Further, MDMA 
exposure produced tolerance to MDMA-induced hypophagia (Zacny, Virus, & 
Woolverton, 1990) reduced drug discrimination sensitivity (Schechter, 1991), and 
blunted MDMA-produced hormonal responses (Baumann et al., 2008). MDMA-
induced tolerance in non-human primates is also well established (Fantegrossi, 2007; 
Fantegrossi et al., 2004; Frederick & Paule, 1997).  
The mechanisms responsible for MDMA-induced behaviours are clearly 
multifaceted often involving complex interactions between 5-HT and DA 
mechanisms. However, as MDMA has been shown to exert its effects predominately 
via the 5-HT system, tolerance to those effects are likely to be due to MDMA’s 
ability to alter the 5-HT system following repeated MDMA exposure.  
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Serotonin (5-HT) System 
Overview 
Serotonin is a biogenic amine which acts as a neurotransmitter extensively 
throughout the central (CNS) and peripheral nervous systems. The cell bodies of 5-
HT neurons are located within nine raphe nuclei (RN) localised along the 
rostrocaudal midline of the brain stem where they project to almost all brain regions 
and the spinal cord. The dorsal (DRN) and median raphe (MRN) are the two major 
nuclei of the ascending serotonergic projections containing approximately 85% of 
the 5-HT neurons found within the brain. The DRN projects predominately to the 
ventral hippocampus, amygdala, lateral septum, striatum, prefrontal and cerebral 
cortex (McQuade & Sharp, 1995; O'Hearn et al., 1988; Underwood, Arango, 
Bakalian, Ruggiero, & Mann, 1999). The MRN innervates the hypothalamus, medial 
septum, dorsal hippocampus and cerebral cortex (Barnes & Sharp, 1999; Hornung, 
2003; Hoyer et al., 1994).  
Serotonin exerts its effects on neuronal activity through the excitatory or 
inhibitory activation of at least 14 genetically, pharmacologically and functionally 
distinct 5-HT receptor subtypes (Barnes & Sharp, 1999; Hoyer et al., 1994; Peroutka, 
Lebovitz, & Snyder, 1981). The 5-HT receptor subtypes belong to seven 
transmembrane domain G-protein coupled metabotropic families with one exception, 
the 5-HT3 receptor group, which is a ligand-gated ion channel. Some receptors such 
as the 5-HT1a, 5-HT2a and 5-HT2c undergo adaptive changes such as changes in 
sensitivity and/or number following prolonged stimulation or following treatments 
that increased 5-HT availability (Aguirre, Frechilla, Garcia-Osta, Lasheras, and Del 
Rio, 1997; Peroutka & Snyder, 1980). As these receptors have been shown to play 
major roles in MDMA-produced effects they will be discussed in more detail below. 
5-HT1 Receptors 
Overview 
A wealth of studies including ligand binding and more recently PET studies, 
have demonstrated that the 5-HT1 receptor is expressed extensively throughout the 
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mammalian CNS (Baker, Halliday, & Tork, 1990; Barnes & Sharp, 1999). The 5-
HT1 receptor family presently includes five subtypes; the 5-HT1a, 5-HT1b, 5-HT1d, 5-
HT1e, and 5-HT1f (Barnes & Sharp, 1999; Hoyer et al., 1994).The subtypes are 
similar in their molecular structure, are negatively coupled to adenylate cyclase via G 
proteins and show a high affinity for 5-HT. Activation inhibits adenyl cyclase 
thereby reducing cellular levels of cyclic AMP (cAMP). Additionally, activation 
initiates a G-protein-activated potassium channel independent of cAMP (Albert, 
Lembo, Storring, Charest, & Saucier, 1996; Pucadyil, Kalipatnapu, & 
Chattopadhyay, 2005). Therefore, 5-HT1 receptors are predominately inhibitory. 
 
5-HT1a Receptor 
Distribution 
Two types of 5-HT1a receptor have been identified; the inhibitory 5-HT1a 
autoreceptor and the 5-HT1a postsynaptic receptor. High density 5-HT1a labelling and 
high levels of 5-HT1a mRNA expression are found in a number of CNS regions, 
including the dorsal raphe nucleus (DRN), hippocampal pyramidal cell layer and 
cerebral cortex (Chalmers & Watson, 1991; Pazos & Palacios, 1985; Pedigo, 
Yamamura, & Nelson, 1981). 
Within the raphe nuclei (RN) and particularly in the DRN and nucleus raphe 
magnus, the 5-HT1a receptor has been located predominately on the cell body and 
dendrites of 5-HT neurons (Gozlan, El Mestikawy, Pichat, Glowinski, & Hamon, 
1983; Riad et al., 2000; Verge et al., 1986) identifying this receptor as a 
somatodendritic autoreceptor. Further, DRN 5-HT1a autoreceptors are predominately 
extrasynaptic at the plasma membrane suggesting activation is reliant on the 
concentration of synaptic 5-HT (Hoyer et al., 1994).  
Post-synaptic 5-HT1a receptors are predominately located in forebrain 
terminal regions with ascending projections from the DRN and MRN. These include 
limbic brain areas such as the hippocampus, lateral septum and limbic cortical areas 
where they are located in principal cells and predominately glutamate pyramidal 
neurons. Medium binding has been detected in the thalamus, hypothalamus and 
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olfactory bulb with lower levels found in the basal ganglia and cerebellum (Gozlan et 
al., 1983; Riad et al., 2000; Verge et al., 1986). 
Mechanism 
The 5-HT1a autoreceptor is activated by 5-HT released through exocytosis 
from 5-HT neurons or alternately from a non-vesicular pool (Adell, Celada, Abellan, 
& Artigas, 2002; Gozlan et al., 1983). Activation results in an inhibitory action on 
cell firing and 5-HT synthesis in the RN and reduction of 5-HT release in the RN and 
forebrain projection areas of the DRN and MRN (Hervas, Bel, Fernandez, Palacios, 
& Artigas, 1998; Sharp, Umbers, & Hjorth, 1996; Sprouse, Bradberry, Roth, & 
Aghajanian, 1989). In vitro agonists with 5-HT1a selectivity, such as 8-OHDPAT, 
mimic this activity by inhibiting raphe cell firing causing a dose dependent decrease 
in 5-HT release. These effects can be reversed by various 5-HT1a antagonists 
including WAY100635 (Bosker, Donker, Klompmakers, Kurata, & Westenberg, 
1994; Davidson & Stamford, 1995; Forster et al., 1995; Gartside, Umbers, Hajos, & 
Sharp, 1995; Gozlan et al., 1983; Penington, Kelly, & Fox, 1993a, 1993b). 
Activation of the 5-HT1a autoreceptor not only has a major impact on 5-HT 
release in the raphe nuclei but also in the forebrain projection areas by modulating 5-
HT activity (Stamford, Davidson, McLaughlin, & Hopwood, 2000). Microdialysis 
and electrophysiological studies showed that the 5-HT1a agonist, 8-OHDPAT, 
infused into the DRN resulted in a decrease of 5-HT release in the striatum, an effect 
blocked by selective 5-HT1a antagonists (Bonvento, Scatton, Claustre, & Rouquier, 
1992; Kreiss & Lucki, 1994). 
Long term stimulation of the 5-HT1a autoreceptor led to alterations in 
sensitivity and an internalisation of the receptor. This consequently may allow an 
increase of neuronal firing and 5-HT release in postsynaptic target areas (Blier & de 
Montigny, 1998; Blier, Pineyro, el Mansari, Bergeron, & de Montigny, 1998; Dong, 
de Montigny, & Blier, 1997; Riad et al., 2000; Riad, Watkins, Doucet, Hamon, & 
Descarries, 2001). In contrast, postsynaptic 5-HT1a receptors remain unchanged 
following continued activity. However, it is suggested that activation of these 
postsynaptic receptors would be increased due to the desensitisation of the 
autoreceptor and result in increased 5-HT release in projection areas (Dong et al., 
1997; Godbout, Chaput, Blier, & de Montigny, 1991) again highlighting the different 
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properties of the 5-HT1a autoreceptor and the 5-HT1a postsynaptic receptor.  These 
studies highlight the high degree and importance of the plasticity of 5-HT1a 
receptors, and especially the 5-HT1a autoreceptor, to 5-HT transmission.  
 
5-HT2 receptors 
Overview 
Three 5-HT2 receptor subtypes have been identified within the mammalian 
CNS; the 5-HT2a, 5-HT2b, and 5-HT2c (Hoyer et al., 1994; Ikemoto et al., 2000; 
Nocjar, Roth, & Pehek, 2002). All three subtypes are G-protein coupled-receptors 
that have low affinity for 5-HT have similar structural, pharmacological and signal 
transduction pathway characteristics (Barnes & Sharp, 1999; Hoyer et al., 1994). The 
5-HT2a and 5-HT2c are the most extensively studied of the subtypes as they are 
widely distributed throughout the CNS while the 5-HT2b receptor is restricted to a 
few brain regions in both humans and rodents (Barnes & Sharp, 1999). The recent 
development of selective 5-HT2 antagonists has enabled some of the functional 
responses of the 5-HT2a and 5-HT2c receptors to be distinguished. 
5-HT2a Receptor 
Distribution 
The 5-HT2a binding sites in the human and rodent CNS show high levels of 
expression in the neocortex, olfactory tubercle, striatum, substantia nigra, 
hippocampus, entorhinal and pyriform cortex, caudate nucleus, nucleus accumbens 
(NAcc), and some brain stem nuclei such as the rostral dorsal raphe (Lopez-
Gimenez, Mengod, Palacios, & Vilaro, 1997; Nocjar et al., 2002; Pazos, Cortes, & 
Palacios, 1985; Pompeiano, Palacios, & Mengod, 1994). The 5-HT2a binding sites 
have been found to map onto the distribution of 5-HT axons arriving from the DRN 
in specific regions such as the frontal cortex, suggesting that they receive selective 
activation by innervations from the DRN (Blue, Yagaloff, Mamounas, Hartig, & 
Molliver, 1988). Studies have also indicated that the 5-HT2a receptor is postsynaptic 
(Lopez-Gimenez et al., 1997). Because these receptors have been detected on DA 
neurons in the rat and human midbrain that project to forebrain regions (Doherty & 
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Pickel, 2000; Ikemoto et al., 2000; Nocjar et al., 2002), they might modulate DA 
neurotransmission.  
Mechanism 
The 5-HT2a receptor modulates the release of several neurotransmitters 
including glutamate, GABA, and DA (Barnes & Sharp, 1999). Microdialysis studies 
revealed that 5-HT2a agonists enhanced DA release in the striatum while 5-HT2a 
antagonism attenuated dopamine release in the ventral tegmental area (VTA) and 
striatum (De Deurwaerdere & Spaminato, 1999; Lucas & Spampinato, 2000). As 5-
HT2a selective agonists are not readily available the behavioural effects of 5-HT2a 
receptor activation have been difficult to determine. The use of selective 5-HT2a 
antagonists in conjunction with 5-HT agonists has, however, permitted some 5-HT2a 
mediated behaviours to be identified. For example, the 5-HT2 agonist, DOI produced 
head twitches in the rat, and this effect was attenuated by 5-HT 2a/c antagonists, 
ketanserin and ritanserin (Kleven, Assie, & Koek, 1997).  
 
5-HT2c Receptor 
Distribution  
The 5-HT2c receptor is widely distributed throughout the CNS (Lopez-
Gimenez, Mengod, Palacios, & Vilaro, 2001; Pompeiano et al., 1994) and is 
localised in the neocortical areas, hippocampus, NAcc, amygdala, striatum, 
amygdala and substantia nigra, olfactory tubercle and DRN. As with the 5-HT2a 
receptor, the 5-HT2c receptor has been identified predominately as postsynaptic 
(Barnes & Sharp, 1999; Lopez-Gimenez et al., 2001).  
Mechanism 
Evidence suggests that activation of the 5-HT2c receptor mediates some of the 
effects of 5-HT in several brain regions and receptor activation modulates dopamine 
transmission. Activation of DA neurons in the rat substantia nigra reticulata by 5-HT 
was blocked by the non-selective 5-HT2c antagonist, ketanserin (Giorgetti & Tecott, 
2004). Systemic administration of 5-HT2c receptor antagonists dose dependently 
increased firing of DA neurons in the VTA. The 5-HT2c antagonist, SB-242084, 
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increased dopamine overflow in the nucleus accumbens and prefrontal cortex as 
measured by microdialysis. Conversely, the 5-HT2c agonist, Ro 60-0175, reduced the 
firing rate of mesolimbic DA neurons resulting in a reduction of DA release in the 
frontal cortex and nucleus accumbens (De Deurwaerdere, Navailles, Berg, Clarke, & 
Spampinato, 2004; Di Matteo, Di Giovanni, Di Mascio, & Esposito, 1999; Gobert et 
al., 2000).  
Several behaviours have been attributed to the activation of 5-HT2c receptors 
including hypolocomotion, hypophagia (Barnes & Sharp, 1999; Kennett et al., 1997) 
and anxiety (Bagdy, Graf, Anheur, Modos, & Kantor, 2001). Many of these 
responses have been obtained following administration of non-selective 5-HT2c 
agonists such as m-CPP (Barnes & Sharp, 1999; Fone, Austin, Topham,, Kennett, & 
Punhani, 1998; Kennett et al., 1997). The availability of highly selective 5-HT2c 
antagonists, such as RS102221 (Bonhaus et al., 1997; Conductier, Crosson, Hen, 
Bockaert, & Compan, 2005), has allowed the contribution of the 5-HT2c receptor to 
be determined.  
 
 
 
Role of 5-HT receptors in the behavioural effects of MDMA  
Acute MDMA 
There is evidence that the 5-HT2a and 5-HT2c receptors contribute to MDMA-
induced hyperactivity (Fletcher et al., 2002; Halberstadt et al., 2009; Kehne et al., 
1996; Ross et al., 2006). Pre-treatment with a range of 5-HT2a antagonists, such as 
ritanserin, ketanserin, SR-46349B, and the highly selective 5-HT2a antagonist, MDL 
100,907, dose dependently attenuated locomotor activity in rats (Ball & Rebec, 2005; 
Herin, Liu, Ullrich, Rice, & Cunningham, 2005; Kehne et al., 1996). In contrast the 
5-HT2c receptor exerts an inhibitory influence on hyperactivity induced by MDMA. 
Antagonists at the 5-HT2c receptor, including SB242084 and SB 206553, dose 
dependently potentiated MDMA-induced hyperactivity (Bankson & Cunningham, 
2002; Fletcher et al., 2002; Fletcher, Sinyard, & Higgins, 2006). These data suggest 
that activation of the 5-HT2a receptor is involved in the generation of MDMA 
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produced hyperactivity while activation of the 5-HT2c receptor attenuates its 
expression. The involvement of the 5-HT1a receptor in MDMA-induced locomotor 
effects remains equivocal as both inhibitory and limited effects have been found 
when 5-HT1a antagonists were administered (Bankson & Cunningham, 2001; Kehne 
et al., 1996; McCreary, Bankson, & Cunningham, 1999). 
It has been suggested that MDMA-induced hyperthermia is mediated by 
activation of 5-HT2a, 5-HT2c and 5-HT1a receptors. Selective and non-selective 5-
HT2a and 5-HT2c antagonists such as MDL 100,907, ketanserin, ritanserin, and R-
96544 blocked MDMA-induced hyperthermia (Fantegrossi et al., 2003; Herin et al., 
2005; Mechan et al., 2002a; Schmidt, Abbate, Black, & Taylor, 1990). However, 5-
HT2b/c antagonists and 5-HT1a antagonists failed to attenuate MDMA-produced 
hyperthermia (Shioda et al., 2008) suggesting a limited role of these receptor 
subtypes. Additionally, the hypothermic response induced by the 5-HT1a agonist, 8-
OHDPAT, was potentiated following single and repeated MDMA exposure, an effect 
correlated with increased 5-HT1a receptor density in the frontal cortex following 
MDMA exposure (Aguirre et al., 1997; Aguirre et al., 1998). It may be suggested 
that 5-HT1a antagonists, through their ability to increase 5-HT release, activate 5-
HT2a receptors and result in a potentiated hypothermic response. 
Alterations in exploratory behaviour induced by MDMA have also been 
shown to involve 5-HT2 and 5-HT1a receptor activation (Bhattacharya, Bhattacharya, 
& Ghosal, 1998; Morley & McGregor, 2000). Decreased exploration of the elevated 
plus maze (EPM) was found following low dose MDMA while higher doses 
increased exploration (Lin et al., 1999). It was suggested that, as 5-HT1a receptors 
have a higher affinity for 5-HT than 5-HT2 receptors, the low dose administration 
activated the 5-HT1a while the higher doses activated 5-HT2 receptors. These studies 
highlight a complex interaction between MDMA and the 5-HT1a and 5-HT2 
receptors. 
 
Repeated MDMA Exposure 
Adaptations in several 5-HT receptor mechanisms have been reported 
following repeated MDMA exposure (McGregor et al., 2003; Reneman et al., 2002; 
Scheffel, Lever, Stathis, & Ricaurte, 1992). Because repeated MDMA exposure 
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produced tolerance to the effects of MDMA as well as to other 5-HT agonists, 
tolerance may reflect these receptor changes.  
There have been few investigations into the effects of MDMA pre-treatment 
on the binding of 5-HT1a and 5-HT2 receptors. Reneman et al. (2002) examined the 
effect of MDMA exposure on 5-HT2a receptor binding densities in several brain 
regions in humans and rats. Rats exposed to MDMA (10mg/kg x2 per day for 4 days 
a total of 80mg/kg) showed significant decreases in 5-HT2a binding densities in the 
frontal, parietal and occipital cortex 6 hours post MDMA with decreased densities 
persisting at 3 days. Thirty days post MDMA an upregulation of 5-HT2a binding sites 
was observed in the frontal cortex while the parietal and occipital cortex returned to 
control levels. Depletions of 5HT were produced in all regions at 6 hours and 3 days 
with the greatest reductions observed at 30 days. Brain imaging also revealed 
reduced 5-HT2a binding in current MDMA users but abstinent users showed 5-HT2a 
upregulation. Because 5-HT2 receptors adapt to synaptic 5-HT levels, it was 
suggested that these alterations resulted from increases in synaptic 5-HT produced by 
MDMA. In another study 5-HT 2a/c receptor binding was measured in rats 10 weeks 
following MDMA exposure (5mg/kg hourly x4 for 2 days, total 40mg/kg). In 
contrast to Reneman et al. (2002), it was found that DOI binding was reduced in 
most brain regions suggesting a more persistent downregulation of the 5-HT2a/c 
receptors (Bull et al., 2004).The conflicting results may reflect the difference in 
MDMA dose or the methods of measurement, however, together the results confirm 
that repeated MDMA exposure produced adaptations in the 5-HT2 receptor 
mechanism.  
Effects of repeated MDMA exposure on 5-HT1a receptor densities have also 
been demonstrated. One week following both single (30mg/kg) and daily high dose 
MDMA (30mg/kg daily for 4 consecutive days) administration increased 5-HT1a 
receptor binding density was observed in the frontal cortex and hypothalamus. In 
contrast, decreased densities were observed in the hippocampus and brain stem, 
including the DRN (Aguirre et al., 1998; Aguirre et al., 1997; Aguirre et al., 1995). It 
was suggested that MDMA’s ability to damage fine 5-HT terminals but not cell 
bodies may account for the opposite results. The increase in the 5-HT1a receptors in 
the frontal cortex was seen as compensation for the regional loss of 5-HT nerve 
terminals and therefore 5-HT synthesis. It is also possible that pre and postsynaptic 
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activation may account for these differences. The DRN has a high density of 5-HT1a 
autoreceptors relative to postsynaptic receptors (Gozlan et al., 1983; Riad et al., 
2000; Verge et al., 1985). Therefore, differential effects may reflect the direct 
response of the 5-HT1a autoreceptors to 5-HT release while adaptations in the 
terminal regions reflect a response to the 5-HT1a autoreceptor activity. In contrast, 
no change in 5-HT1a binding was reported 3 months following MDMA exposure (4 x 
5 mg/kg over 4 h over 2 days) (McGregor et al., 2003). The varying results may be 
due to the time differences of measurement and MDMA doses.   
Behavioural studies more consistently suggest that 5-HT receptors undergo 
neuroadaptations following repeated MDMA exposure. However, studies examining 
the consequences of repeated MDMA exposure on 5-HT1a and 5-HT2 receptor 
function and expression are limited. A few studies have attempted to identify 
functional changes by using specific pharmacological challenges in selected 
behavioural tests. 
Bull, Hutson, & Fone (2003) investigated the effect of MDMA pre-treatment 
in Lister Hooded rats. Rats received MDMA (15mg/kg) twice daily for 3 days. 
Effects of the 5-HT2 agonist, m-CPP, were examined in the elevated plus maze 
(EPM), social interaction and locomotor activity tests. As has been reported in 
another study (McGregor et al., 2003), MDMA pre-treated rats showed reduced 
social interaction three weeks following MDMA exposure. Two days later the effects 
of m-CPP (2.5mg/kg) were determined. Hypolocomotion induced by m-CPP was 
unaltered by MDMA pre-treatment. Four days later m-CPP (1.0mg/kg) produced a 
reduction in open arm exploration on the EPM but there was no effect of MDMA 
pre-treatment. Because these behaviours have been attributed to activation of 5-HT2c 
receptors (but see File, 1992; Griebel, Perrault, & Sanger, 1997), it was suggested 
that repeated MDMA did not modify these receptors. The use of only a single dose 
of m-CPP, however, limits the interpretation. In follow-up study Bull et al. (2004) 
pre-treated rats with MDMA (5mg/kg hourly for 4 hours on 2 consecutive days) and 
eight weeks later administered the 5-HT 2a/c agonist, DOI. DOI reduced exploration 
in saline but not MDMA pretreated rats suggesting a desensitised 5-HT2a receptor. 
Altered 5-HT2a sensitivity following MDMA pre-exposure has also been 
found in the absence of changes in receptor density.  Sprague Dawley rats were 
administered MDMA (10mg/kg 2x daily 4x every 5th day) and challenged with DOI. 
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Repeated MDMA potentiated DOI-induced head twitches and back muscle 
contractions suggesting that MDMA exposure enhanced sensitivity of 5-HT 2a/2c 
receptors (Biezonski, Courtemanche, Hong, Piper, & Meyer, 2009) even though 
binding densities remained unchanged. The lack of change in 5-HT2a/c binding 
suggests that differing pre-treatment regimens can alter receptor function without 
increasing receptor expression (Richtand et al., 2003; Shuto, Seeman, Kuroiwa, & 
Nishi, 2008).  
The effect of repeated MDMA exposure on the behavioural responses of 5-
HT1a receptor ligands has also been investigated. MDMA pre-treatment produced 
tolerance to behaviours induced by the 5-HT1a agonist, 8-OHDPAT, including 
components of the 5-HT syndrome such as flat body posture and forepaw treading. 
Conversely, tolerance to the hypothermic or locomotor activating effects of 8-
OHDPAT were not produced (Granoff & Ashby, 2001). As the various brain regions 
involved in 8-OHDPAT mediated behaviours remain to be elucidated these findings 
may indicate region specific alterations in 5-HT1a function. Furthermore, pre or 
postsynaptic 5-HT1a activation may lead to varying results. Flat body posture has 
been reported following 8-OHDPAT application into the DRN suggesting the 
contribution of 5-HT1a autoreceptors (Higgins & Elliott, 1991) however, as 5-HT1a 
heteroreceptors are also present within the DRN albeit at a low ratio to presynaptic, 
specific contributions of the two receptor types can be difficult to dissociate.  
Enhanced MDMA-produced behavioural responses mediated by 5-HT1a 
receptor activation have also been found following repeated neonatal MDMA 
exposure. Enhanced MDMA-produced serotonin syndrome behaviours, including 
head weaving and forepaw treading, and hyperthermic response were produced in 
adults following neonatal exposure (Piper & Meyer, 2004; Piper et al., 2005). These 
changes in sensitivity to MDMA may reflect an alteration in receptor number or 
supersensitivity of the 5-HT1a receptor population that mediate each behaviour. 
While this is yet to be elucidated these studies highlight the adaptability of the 5-
HT1a receptors, both pre and postsynaptic, following MDMA exposure.  
A consistent observation has been that repeated MDMA produces deficits in 
tissue levels of 5-HT and its primary metabolite 5-Hydroxyindoleacetic acid (5-
HIAA) as well as reductions in SERT binding following high dose MDMA pre-
treatment. Reductions in 5-HT and 5-HIAA tissue concentrations were evident in the 
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striatum, frontal cortex, hippocampus, amygdala, nucleus accumbens, olfactory 
tubercle and caudate one to four weeks following repeated MDMA exposure 
(Aguirre et al., 1998; Battaglia et al., 1987; Granoff & Ashby, 2001) and decreased 
SERT binding in cortical, hippocampal, thalamic, and hypothalamic sites was 
reported (Battaglia et al., 1987; McGregor et al., 2003). Several of these studies 
suggested that these deficits mediated behavioural tolerance (Callaway & Geyer, 
1992; Scanzello, Hatzidimitriou, Martello, Katz, & Ricaurte, 1993; Shankaran & 
Gudelsky, 1999).  
Microdialysis studies have reported blunted synaptic 5-HT overflow in 
response to MDMA following repeated high dose MDMA administration. Prior 
MDMA exposure reduced 5-HT release in the frontal cortex and striatum in response 
to MDMA or the 5-HT releasing stimulant, fenfluramine (Gartside, McQuade, & 
Sharp, 1996; Matuszewich, Filon, Finn, & Yamamoto, 2002; Series, Cowen, & 
Sharp, 1994; Shankaran & Gudelsky, 1999). Reduced striatal release was 
accompanied by attenuated hyperthermic and 5-HT syndrome responses (Shankaran 
& Gudelsky, 1999). Other studies have reported impaired 5-HT release following 
high dose MDMA pre-treatment in response to physiological or stressful stimuli 
(Gartside et al., 1996; Matuszewich et al., 2002). Together, these studies suggest that 
tolerance to the effects of MDMA may reflect impairments in 5-HT transmission 
under circumstances in which the 5-HT system is challenged. However, there is an 
ongoing debate as to whether MDMA-induced impairments reflect neuroadaptive 
changes or neurotoxicity (Baumann, Wang, & Rothman, 2007).  
Neurotoxicity vs. Neuroadaptations 
There is extensive evidence that across a variety of species including rats 
(Commins et al., 1987), guinea pigs (Colado, O'Shea, & Green, 2004) and non-
human primates (Fantegrossi, Ullrich, Rice, Woods, & Winger, 2002; Ricaurte et al., 
1988) MDMA produces changes in neuronal markers which may indicate 
degeneration in 5-HT mechanisms. Following acute administration of MDMA there 
is an acute rapid release of 5-HT, a subsequent depletion of 5-HT and an inactivation 
of tryptophan hydroxylase. The 5-HT tissue deficits recover within 24 hours but 
tryptophan hydroxylase inactivation persists (Schmidt, Levin, & Lovenberg, 1987; 
Stone et al., 1989b).  
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Neurotoxic type effects appear in the second phase, occurring between 24 
hours and 1 week following MDMA administration. These effects include long term 
inhibition of tryptophan hydroxylase activity, a reduction in reuptake sites and 
reduced 5-HT and 5-HIAA tissue levels (Battaglia et al., 1988; Commins et al., 1987; 
Scanzello et al., 1993). While it is unequivocal that repeated MDMA exposure 
produces 5-HT deficits, few studies have shown other established markers of 
neurotoxicity, such as degeneration of nerve terminals and reactive gliosis. 
Administration of 80 mg/kg of MDMA twice a day for 2 days to rats was followed 
by a degeneration of 5-HT axons in the striatum and somatosensory cortex as 
determined by silver staining (Commins et al., 1987). In another study rats were 
injected twice daily with 75-150mg/kg MDMA for two days (Jensen et al., 1993). 
The levels of glial fibrillary acidic protein (GFAP) which, if expression is enhanced 
is a marker of reactive gliosis(O'Callaghan & Miller, 1993), was markedly elevated 
in several brain regions (Commins et al., 1987; Molliver et al., 1990; O'Hearn et al., 
1988).  
However, as these pre-treatment regimes used extremely high dose exposures 
it is questionable as to whether they are meaningful. With lower dose administrations 
that produced 5-HT depletions nerve degeneration or gliosis was not observed. For 
example, administration of MDMA (7.5 mg/kg, IPQ 2 h x 3 doses) markedly 
decreased levels of 5-HT in the cortex and hippocampus but there was no effect on 
the expression of GFAP (Wang, Baumann, Xu, Morales, & Rothman, 2005; Wang, 
Baumann, Xu, & Rothman, 2004). Further, rats administered twice daily injections 
of 20mg/kg MDMA for 4 days showed decreased SERT binding but no reactive 
gliosis (Pubill et al., 2003). While MDMA-induced 5-HT depletions can last for 
several months to years there is evidence of recovery (Brennan & Schenk, 2006; 
Scanzello et al., 1993). One year post MDMA pre-treatment recovery of 5-HT 
markers was found in all brain regions. Brain 5-HT and 5-HIAA levels also showed 
recovery with time in rats. One year post MDMA treatment (10mg/kg 4x 2 hourly) in 
most rats there was complete recovery in all brain regions examined (Scanzello et al., 
1993). Additionally, paroxetine binding studies following MDMA administration 
have shown time dependent recovery (Lew et al., 1996).  
MDMA-induced behavioural effects have also shown to recover following 
repeated MDMA exposure. Two weeks following an MDMA pre-treatment regimen 
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rats were tolerant to the locomotor activating effects of MDMA. There was, however, 
recovery 12 weeks following treatment (Brennan & Schenk, 2006).These studies 
suggest that, while some individuals may be more susceptible to permanent deficits, 
the majority may recover following abstinence. 
 
Summary 
 MDMA produces long term changes in 5-HT neurochemistry. However, 
studies suggest that these deficits are not associated with toxicity markers such as 
cell death and reactive gliosis and therefore do not reflect neuronal damage 
equivalent to toxicity. Tolerance to the behavioural effects of MDMA has been 
observed following doses that act on the 5-HT system yet do not induce other 
markers of toxicity such as reactive gliosis. Therefore, the underlying mechanisms of 
MDMA-induced tolerance are most likely due to neuroadaptations in response to 
repeated MDMA.  
Following repeated MDMA tolerance to many of the effects produced by 
MDMA is evident. Additionally, MDMA depletes 5-HT and 5-HIAA levels, and 
produces 5-HT receptor adaptations. Of these the 5-HT1a, 5-HT 2a/c receptors have 
been shown to undergo adaptations following repeated MDMA exposure. Together, 
these findings suggest that these alterations to the 5-HT system play a role in 
MDMA-induced behavioural tolerance, although the underlying mechanisms remain 
unclear.  
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Present Study 
There are three aims of this thesis. The first was to develop a behavioural 
paradigm that was sensitive to 5-HT probes in order to assess the effects of MDMA 
exposure on receptor function. The second was, to measure changes in specific 
receptor function as a result of MDMA pretreatment. The third was to use selective 
ligands and exposure in an attempt to reverse tolerance 
 
Section 1 
Behavioural Assay Development 
The driving hypothesis was that there was altered 5-HT receptor function 
underlying behavioural tolerance. Section 1 describes the development of a 
behavioural assay in which the effects of MDMA administration could be observed. 
This assay makes use of a variation of an Emergence Test (ET). The ET was chosen 
as it has been shown to be sensitive to effects attributed to 5-HT and specifically 5-
HT2 receptors (Griebel, 1995). Additionally, effects of MDMA have been 
documented using the paradigm (Morley, Gallate, Hunt, Mallet, & McGregor, 2001; 
Morley & McGregor, 2000). Furthermore, this model is advantageous as it does not 
require conditioning, punishment, or reward thereby limiting the type of response 
evoked.  
 
The Emergence Test 
The principle known as “Neotic” preference, first described by Fehrer in 
1956, is based on an animal’s natural preference to readily explore a novel 
environment over a familiar one (Fehrer, 1956; Hughes, 2007). The emergence test, 
based on this principle, is a behavioural assay that measures the animal’s latency to 
move freely between a familiar area (the hide box) and an area not previously 
encountered (the test arena) (Crawley & Goodwin, 1980; Hascoet, Bourin, & 
Dhonnchadha, 2001; Pare, Tejani-Butt, & Kluczynski, 2001). The procedure requires 
the rat to be placed in a fully enclosed hide box situated within an open arena. 
Following a habituation period the experimenter opens a slide door along one side of 
the hide box allowing the rat to emerge into the test arena. The latency to emerge 
  
31 
from the hide box into the open arena is then measured. Figure 1 below shows the ET 
apparatus. In the top panel the hide box is placed in the test arena and kept closed 
during the habituation period. The panel below shows the animal emerging from the 
hide box into the novel test arena once the hide box has been opened by the 
experimenter. 
 
Figure 1 The Emergence Test.  
 
MDMA typically produced decreased exploratory behaviour in the 
emergence test (ET) (Morley et al., 2001; Morley & McGregor, 2000). It is well 
established that several experimental factors can impact on baseline responses as 
well as pharmacologically-induced behaviours in animals. These include handling, 
exposure to the environment, drug and drug doses, pretreatment times, administration 
routes, species and strain (Griebel et al., 1997; Schmitt & Hiemke, 1998; van Driel & 
Talling, 2005).Therefore, the present study investigated the effects of prior test 
exposure, handling, and drug exposure on MDMA responses in the ET and adopted 
particular methods based on these results.  
MDMA administration produces an acute dose dependent hyperactivity 
response (Callaway et al., 1990; Kehne et al., 1996; McCreary et al., 1999; Spanos & 
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Yamamoto, 1989). Therefore, when developing a procedure in which locomotor 
activity may influence the measured behaviour, it is necessary to demonstrate 
dissociation between these two behavioural responses. In the ET this hyperactivity 
may reduce or increase emergence latency thereby confounding the results. Hence, 
the first experiment established a dose response curve for MDMA-produced 
hyperactivity. Following this, MDMA doses were chosen for testing in the ET that 
did not affect locomotor activity.   
In order for the ET to reflect a behavioural paradigm based on “Neotic” 
preference the concept of novelty was addressed within the test itself and through 
repeated exposure to the test. Firstly, within the ET two environments were required; 
one familiar and one novel (Hughes, 2007). The present study provided a habituation 
period in the hide box, in which the animal was initially placed, to establish a 
familiar environment. The test arena, to which the animal was exposed once the slide 
door was opened, was then considered the novel environment. Secondly, it has been 
reported that the novelty of an environment depends on the animal’s previous 
experience with that environment (Hughes, 2007). Studies have shown a reduction in 
responses such as the number of punished crossings in the four plates test and 
decreased open arm exploration in the EPM, on second and subsequent trials (File, 
1990; File, Mabbutt, & Hitchcott, 1990; File, Zangrossi, Viana, & Graeff, 1993). 
Additionally, drug response was altered following test re-exposure. For example, the 
response to diazepam was eliminated following prior test exposure (Hascoet, Bourin, 
& Couetoux du Tertre, 1997). In order to determine if the animals could be 
repeatedly tested, thereby minimising the number required, rats were re-exposed to 
the test over a number of days and baseline and MDMA-induced behavioural 
responses were measured. Whether or not re-exposure to the test arena altered 
subsequent baseline and MDMA responses would determine if experiments were to 
be between or within subjects.  
It has been reported that the extent of handling can also influence responses 
in the ET. Studies show that following one week of daily handling rats displayed 
higher levels of activity compared to those handled only on test days (Schmitt & 
Hiemke, 1998). Accordingly, this variable was investigated in order to assess the 
effects on baseline and MDMA-produced changes in EL. EL of animals with no 
prior handling were compared to those that received handling on days 1, 5 and 9.  
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Section 2 
Section 2 utilises the ET in conjunction with pharmacological agents to assess 
changes in receptor function as a result of MDMA exposure. The effects of MDMA 
and the 5-HT agonists, m-CPP and fenfluramine, were examined in the ET. m-CPP 
was chosen as it has been shown to act preferentially as a 5-HT2c agonist (Fiorella, 
Rabin, & Winter, 1995; Hamik & Peroutka, 1989; Kennett & Curzon, 1988; Kennett 
et al., 1994) and to release 5-HT via the 5-HT transporter (Baumann, Mash, & 
Staley, 1995; Pettibone & Williams, 1984). m-CPP decreased exploratory behaviour 
has been attributed to activation of 5-HT2c receptors (Bilkei-Gorzo, Gyertyan, & 
Levay, 1998; Griebel et al., 1997). Fenfluramine is a 5-HT transporter substrate and 
potent 5-HT releaser (Berger, Gu, & Azmitia, 1992; Rothman & Baumann, 2002). 
DOI is a preferential 5-HT 2a agonist that produces a range of behavioural responses 
including wet dog shakes and head twitches (Kleven et al., 1997; Willins & Meltzer, 
1997). In addition, DOI altered exploratory behaviour on the elevated plus maze 
(Bull et al., 2004; Kennett et al., 1994). These effects have been attributed to 5-HT2a 
receptor activation because they were attenuated by the 5-HT2a but not 5-HT2c 
antagonists (Kennett et al., 1994; Willins & Meltzer, 1997). In addition to MDMA 
these pharmacological probes would help to elucidate the contribution of specific 
receptors in emergence latency in the ET. The highly selective 5-HT2c antagonist, 
RS102221 (Bonhaus et al., 1997), was administered to determine the contribution of 
this
 
receptor subtype. All drug pretreatment times were established by reviewing 
previous literature in combination with peak effect times established in our 
laboratory. 
 
MDMA Pre-treatment Regimen  
In order to investigate the effects of repeated MDMA exposure in the ET the 
MDMA pre-treatment regimen (10mg/kg, 4x 2hr, IP) and 2 week withdrawal period 
were chosen for the present study as 5-HT deficits and behavioural tolerance 
following this procedure are well established (Brennan & Schenk, 2006; Nair & 
Gudelsky, 2006; Scanzello et al., 1993; Shankaran & Gudelsky, 1999; Sumnall et al., 
2004). This time frame was also chosen because deficits in tissue 5-HT and 5-HIAA 
concentrations, dialysate 5-HT, and alterations to 5-HT receptors have been 
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demonstrated (Renman et al., 2002; Shankaran & Gudelsky, 1999). In order to verify 
that the dosing regimen used produced 5-HT deficits, 5-HT and 5-HIAA tissue levels 
were measured using HPLC analysis, as described in the method section.  
It has previously been reported that following high dose MDMA 
administration tissue 5-HT and 5-HIAA levels are depleted and 5-HT release 
impaired. Further, MDMA-induced behaviours were attenuated suggesting tolerance. 
However, baseline dialysate 5-HT levels were unaltered (Granoff & Ashby, 
2001).These results suggest that despite significant depletions the 5-HT system is 
able to maintain a baseline concentration of synaptic 5-HT. While reductions in the 
SERT binding sites and decreased MAO activity following high dose MDMA 
exposure may contribute to maintaining the synaptic 5-HT levels through limiting 
reuptake and degradation, the reduced ability to release 5-HT is evident when the 
system is challenged. In order to detect any effect of intervention the current study 
investigated both baseline and challenged groups.  
 
Section 3  
Section 3 investigates the functional status of the 5-HT1a receptor by 
determining the response to a 5-HT1a agonist following MDMA pretreatment.The 5-
HT1a agonist, 8-OHDPAT, has been extensively used to investigate the functional 
status of the 5-HT1a receptors (Hillegaart, 1991; Hjorth, 1985). 8-OHDPAT has 
consistently been shown to induce a hypothermic response in rats (Hillegaart, 1991; 
Hjorth, 1985; Renoir et al., 2008) with low dose (<.05mg/kg) preferentially targeting 
the presynaptic 5-HT1a autoreceptor (Hoyer, Hannon, & Martin, 2002). In the present 
study, rectal temperature was measured fifteen minutes prior to 8-OHDPAT 
administration and again 15, 30 and 45 minutes post injection. In line with previous 
studies (Hjorth, 1985) it was established that a peak hypothermic effect was achieved 
30 min post injection in drug naïve rats. Dose-response curves for 8-OHDPAT 
produced hypothermia were then compared for MDMA and saline pretreated groups.  
 
Sections 4 and 5  
In order to determine the ability of the 5-HT1a antagonists to reverse tolerance 
to MDMA-induced hyperactivity two approaches were used; 1) systemic application 
and 2) local antagonist application targeting the 5-HT1a receptor in the DRN. In order 
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to measure the functional response following 5-HT1a antagonist administration 
locomotor activity was chosen because of the ability for time-course measurements 
that are not easily obtained in the ET. 5-HT1a receptors have also been implicated in 
feeding (Dourish et al., 1985; Fletcher et al., 1996) and so food consumption 
following 5-HT1a antagonist administration was measured.   
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General Methods 
 
Subjects 
 
The subjects were male Sprague-Dawley rats weighing between 200-250gm. 
The animals were bred in the vivarium at Victoria University of Wellington, New 
Zealand. The humidity (74%) and temperature (21° C) controlled colony was 
maintained under a 12:12 hr light/dark cycle with lights on at 0700. Food and water 
were available ad libitum except during testing. All experimental protocols were 
consistent with OLAW regulations and approved by the Animal Ethics Committee of 
Victoria University. 
 
Apparatus 
Locomotor Activity 
Forward locomotion activity was measured using the Activity Monitor 
Version 5 program (Med Associates Inc.). This system consisted of a perspex-lined 
open-field chamber (50 x 50 x 20cm). Each sound attenuated chamber was equipped 
with 16 infrared sources and sensors evenly distributed around the periphery of the 
chamber, a system power supply, an environmental data source controller, 
connecting cables, PC/ environment interface card and data analysis software. The 
chambers were interfaced with a computer that recorded each beam interruption by 
the subject as a forward locomotion count. The program achieved this by dividing 
the chamber into zones. The zone size was able to be predetermined and was, for 
these experiments, set to be the approximate dimensions of a 250gm rat.  When the 
animal travelled distance and crossed the zone perimeters into the adjacent zone, the 
program registered this as an ambulatory (activity) count.  
Emergence Latency 
Emergence latency was measured using a method developed by Pare et al. 
(2001). For the emergence test a wooden hide box (25 x 17 x 20.5cm) was placed in 
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the top left corner of the open-field chamber. The hide box was designed with a 
hinged lid, through which the rat could initially be placed. Following a 
predetermined habituation period the sliding door was opened to allow emergence. 
Full body emergence from the hide box was determined when the distance travelled 
by the rat was equivalent to the length of the rat as measured by Med Associates 
software.  
Infrared videos cameras located above the test chambers recorded and 
monitored activity continuously without disruption. These were used to verify 
emergence and to observe qualitative behaviours as required. The temperature (21° C) 
and humidity (53%) controlled testing room was illuminated with red light (50W), 
and subject to white noise (80dB). Before and after each test the arenas, hide boxes, 
and maze arms were wiped with Virkon ‘S’ disinfectant (Southern Veterinary 
Supplies, Palmerston North). Tests were conducted in the dark between 0800 and 
1700 hr. Experimenters remained outside the test room during experiments.  
Temperature 
Rectal temperature was obtained using a lubricated digital thermometer probe 
(Surgipack Digital Thermometer, Code 6344) inserted 4cm into the rectum. The rat 
was lightly restrained by hand until the temperature stabilised, (no longer than 30 sec 
at any time), a method adopted from Ho et al. (2004). All readings were taken in the 
temperature controlled (21° C) home room. 
Food Consumption 
In section 4 food consumption was recorded on day 1 and 8 following the 
administration of WAY100635. A measured amount of food was placed inside the 
home cage on a daily basis, weighed the following day and the difference calculated 
as the amount consumed. The home cage was searched for any food being placed in 
the area by the animal and taken into account.  
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Pharmacological Procedures 
MDMA Pre-treatment Regimen 
 On day 1 rats were placed in individual cages and administered a regimen of 
4 injections of either MDMA (10mg/kg per injection, I.P) or the saline vehicle at 2 
hourly intervals (total MDMA exposure = 40mg/kg over 6 hours). This regimen was 
chosen because of its reported ability to produce serotonin deficits two weeks 
following treatment (Scanzello et al., 1993; Shankaran & Gudelsky, 1999; Sumnall 
et al., 2004) and to produce tolerance to MDMA-induced hyperactivity (Shankaran & 
Gudelsky, 1999).  
On day 2 rats were housed in pairs for a two week period before behavioural 
tests commenced. Rats were closely monitored during and following the pre-
treatment regimen. When of interest, temperature was recorded 15 min prior to and 
30 min following the last MDMA pre-treatment injection. Overall, the drug regimen 
was well tolerated.  
 
Neurochemical Procedures 
Brain Dissection 
In order to determine brain 5-HT and 5-HIAA concentrations rats were 
asphyxiated by C0², decapitated and brains rapidly removed. In line with the methods 
developed by Heffner, Hartman, & Seiden (1980) the brains were then placed in a 
stainless steel brain block for dissection into 1mm coronal slices. Slices were placed 
onto an inverted petrie dish chilled by ice. The frontal cortex, striatum, nucleus 
accumbens, hippocampus, hypothalamus and dorsal raphe were dissected out, placed 
in vials, weighed, and tissue weights recorded. All samples were stored at -80º C 
until analysed.  
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HPLC analysis 
For the determination of tissue neurotransmitter concentrations High 
Performance Liquid Chromatography (HPLC) with electrochemical detection was 
used. Tissues were removed from the freezer, homogenised in 0.1 N perchloric acid 
and centrifuged at 10 000g for 30 min at 4º C. The supernatant was filtered and 
injected into a high-performance liquid chromatography system (Agilent 1100 series) 
with electrochemical detection. The injection volume was 10 µL for the striatum and 
20 µl for the other regions. 5-HT and 5-HIAA were separated using a C18 reversed 
phase column (150 × 4.6 mm, 5 µm particle size; Eclipse XDB-C18, Agilent, USA). 
The mobile phase consisted of NaH2PO4 (75 mM), octane-1-sulphonic acid 
(1.7 mM), EDTA (0.25 mM), triethylamine (100 µL/L) and methanol (10%), and 
was adjusted to pH 3 with phosphoric acid. The flow rate was 1 ml/min. Detection 
was performed using a coulometric detector (Coulochem III, ESA, USA). The guard 
cell potential was set at 450 mV and the analytical cell potential at 400 mV. 
Chromatograms were acquired with ChemStation software. Concentrations are 
expressed as ng per mg of tissue. Working external standards (500 -15.125ng/ml in 
0.1N perchloric acid) were prepared daily from external standard stock solutions. 
 
Drugs  
 
• +/- 3,4- Methylenedioxymethamphetamine hydrochloride (MDMA, 
ESR, Porirua, New Zealand), dissolved in a solution of 0.9% saline  
• 1-(3-chlorophenyl) piperazine hydrochloride (m-CPP, Tocris), 
dissolved in a solution of 0.9% saline  
• +/-2,5-dimethoxy-4-iodo-phenylisopropylamine (DOI, Sigma 
Aldrich), dissolved in a solution of 0.9% saline 
• (+) - Fenfluramine hydrochloride (fenfluramine, Sigma Aldrich) 
dissolved in a solution of 0.9% saline.  
• 8-[5-(2,4-dimethoxy-5-(4-
trifluoromethylphenylsulphonamido)phenyl-5-oxopentyl]-1,3,8-
  
40 
triazaspiro[4.5]decane-2,4-dione hydrochloride (RS102221, Tocris), 
suspended in a solution of 1% polysorbate 80 (Tween 80 ®).  
• ±8-hydroxy-2-(di-n- propylamino) tetralin (8-OHDPAT, Tocris), 
dissolved in sterile distilled water.  
• N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-2-
pyridinylcyclohexanecarboxamide maleate (WAY100635, Sigma 
Aldrich), dissolved in a solution of 0.9% saline 
 
Injections were intraperitoneally (IP) or subcutaneously (SC) administered 
as noted, in a volume of 1.0 ml/kg with intracranial injections (IC) at a concentration 
of 0.5µg/0.5µl (500ng). All drugs were prepared immediately prior to administration 
and drug weights refer to the salt. 
 
Statistical Analyses 
All analyses were conducted using SPSS statistical package (SPSS Inc) 
version16.0 for Windows 2005. All experimental sample sizes are located on relative 
figures. 
 
 
 
 
 
 
  
41 
Section 1: Emergence Test  
Overview 
The aim of Section 1 was to develop a behavioural assay that was a reliable, 
consistent and sensitive measure of the effects of acute MDMA. This was achieved 
by determining effective doses of MDMA, pretreatment times and procedural 
parameters that were required to elicit optimal MDMA effects.  
In the first experiment a dose effect curve for MDMA-induced locomotor 
activity was determined. In the second experiment separate groups of rats were tested 
following three habituation periods (15, 30, and 45min) in the Emergence Test (ET). 
These times were chosen as it has previously been shown in our laboratory that when 
rats are first placed in an activity box there are initially high levels of activity which 
abate over the first 15minutes. Therefore, prior to MDMA exposure, the rats were 
habituated to the hide box to reduce activity to baseline levels. Secondly, this would 
allow the animals to become familiar with the hide box creating a contrast to the test 
arena which remains novel as required in the ET. Thirdly, as MDMA effects are 
known to peak around 30 min post administration these habitation times would 
provide a window for MDMA-induced behaviours.  
The third experiment examined the effect of repeated exposure to the ET. 
Rats were repeatedly run in the ET over 3 days (day1, 5, and 9). The number of days 
between tests days was chosen as MDMA is known to have a relatively long half life 
of 8 hours and is fully eliminated within 48 hours following administration 
(McCreary et al., 1999).  
Finally, the fourth experiment examined the effect of repeated MDMA 
exposure on emergence latency and experiment 5 examined the effect of repeated 
handling.  
 
MDMA-Produced Hyperactivity 
Separate groups of drug naïve rats were placed in the activity chambers, 
habituated for 30 minutes then administered MDMA (0.0, 1.0, 3.3, 10.0mg/kg, IP). 
Locomotor activity was recorded for a further 60 minutes.  
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MDMA Effects on Emergence Latency 
Effects of MDMA on Emergence Latency as a function of Habituation Time  
The effect of acute MDMA (0.0, 1.0, 3.3mg/kg, IP) administration on 
emergence latency was assessed following three habituation periods (15, 30, 45 min) 
in separate groups of drug naïve rats. Rats were placed in the hide box and given a 
15, 30, or 45 mintue habituation period, the slide door was then opened and testing 
continued until either the rat emerged or 30 min had elapsed.  
Effects of Repeated Exposure to Emergence Test on Emergence Latency 
MDMA doses and habituation period were based on results from preliminary 
work (see Experiment 1 and 2). Experiment 1 demonstrated that MDMA doses 0.0, 
1.0 and 3.3mg/kg failed to increase locomotor activity above baseline. Experiment 2 
revealed that the dose of 3.3mg/kg, following a 30 min habituation period, produced 
a significant increase in emergence latency. Hence, the effect of repeated exposure to 
the test arena on emergence latency was investigated utilizing a 30 min habituation 
period with MDMA doses of 0.0 and 3.3mg/kg.  
On test day 1 separate groups of drug naïve rats were injected with MDMA 
(0.0, 3.3mg/kg, IP) and placed into the hide box for a 30 minute habituation period. 
Following habituation, the slide door was opened and testing continued for a further 
30 min. At the end of the test period the animals were returned in a group cage until 
the next testing day. Testing was conducted on days 1, 5, and 9. 
Effects of Repeated MDMA exposure on Emergence Latency  
The effect of repeated MDMA (0.0, 3.3mg/kg, IP) exposure was assessed in 
four groups of drug naïve rats. On days 1 and 5 rats were weighed then injected with 
MDMA (0.0 or 3.3mg/kg, IP) in the home cage. On day 9 rats were weighed, taken 
to the test room in a group cage, then injected with MDMA (0.0 or 3.3mg/kg, IP) and 
placed in the hide box. Following a 30 min habituation period, the slide door was 
opened and testing continued for 30minutes.  
Effects of Handling on Emergence Latency 
The effect of handling was examined in drug naïve rats. On day 1 and 5 rats 
were either handled or left unhandled in their home cages. On day 9 rats were 
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injected with MDMA (0.0 or 3.3mg/kg), placed in the ET and emergence latency 
measured as above.  
 
Results 
MDMA-produced Hyperactivity 
Dose Effects of MDMA administration on Locomotor Activity 
Figure 2 shows the effect of MDMA (0.0, 1.0, 3.3, 10.0 mg/kg) on locomotor 
activity. Figure 2A shows the time course for the effects of MDMA (0.0, 1.0, 3.3, 
10mg/kg) on locomotor activity. A 2-Way ANOVA (time X MDMA dose), with 
time as a repeated measure, revealed a significant interaction between these factors 
(F(33,352) = 7.292, p < .01) and a main effect of dose (F(3,32) = 36.34, p < .01). 
Post hoc analyses revealed that the MDMA dose 10.0mg/kg significantly increased 
locomotor activity above baseline while 1.0 and 3.3mg/kg doses were ineffective. 
Figure 2B shows the total activity counts post MDMA (0.0, 1.0, 3.3, 10mg/kg) 
administration. A 1-Way ANOVA revealed a significant main effect of MDMA dose 
(F(3,35)=60.74, p<.01). Post hoc tests showed that MDMA 10.0mg/kg significantly 
increased locomotor activity while 0.0, 1.0, and 3.3mg/kg doses had no effect.  
Therefore, a maximum dose of 3.3mg/kg MDMA will be utilised for future 
experiments measuring emergence latency.
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Figure 2 Activity counts produced following MDMA (0.0, 1.0, 3.3, 10.0mg/kg, IP) 
administration (+SEM). The top panel shows the time course of the mean 
activity counts where MDMA was administered at time=0 (Figure 2A). The 
bottom panel shows the total activity counts produced for the 60 minute period 
post MDMA injection (+SEM) (Figure 2B). Significant difference relative to 
vehicle group * p<.05. 
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MDMA effects on Emergence Latency  
Effects of Acute MDMA administration on Emergence Latency over Three 
Habituation Periods 
Figure 3 shows the effect of MDMA doses (0.0, 1.0, 3.3mg/kg) after a 15 
(Figure 3A), 30 (Figure 3B), and 45 min (Figure 3C) habituation period, on mean 
emergence latency. Separate 1-Way ANOVAs on emergence latency as a function of 
MDMA dose revealed that, following the 15min habituation (F(2,37) = 1.211, p > 
.05), and 45 min habituation period (F(2,40) =2.904, p > .05), MDMA failed to 
produce an effect on emergence latency. It was found that a 30min habituation period 
(F(2,40) = 10.764, p <.01) was required in order to observe increased latency effects 
of MDMA administration. Post hoc Tukey analyses revealed that the MDMA 
3.3mg/kg dose significantly increased emergence latency compared to controls, 
while MDMA 1.0 was ineffective.  
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Figure 3 Effect of various MDMA (0.0, 1.0, 3.3mg/kg, IP) doses on emergence 
latency (min) following a 15 min (Figure 3A), 30 min (Figure 3B) and 45min 
(Figure 3C) habituation period (+SEM). Significant difference relative to 
vehicle group * p<.05.
Effects of Repeated Exposure to the Emergence Test following acute MDMA on 
Emergence Latency.  
Figure 4 shows the effect of repeated exposure to the emergence test 
following MDMA exposure on mean emergence latency. A 2-Way ANOVA 
revealed an interaction between day and MDMA dose (F(2,28) =7.96, p < 0.01) 
indicating that repeated exposure to the novel environment significantly decreases 
the MDMA effect.  A 1-Way ANOVA revealed a significant main effect of day 
with MDMA dose 3.3mg/kg (F(2,21) = 7.00, p < .01) but not saline (F(2,21)=1.21, 
p>.05). Post hoc tests showed a significant decrease in emergence latency from 
day 1 to day 9 with MDMA (3.3mg/kg) dose.  
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Figure 4 Effect of repeated exposure to the emergence test on days 1, 5 and 9 
on emergence latency (min) following MDMA (0.0, 3.3mg/kg, IP) 
administration (+SEM). Significant difference relative to MDMA (3.3mg/kg) 
day 1 * p<.05. 
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Effects of Repeated MDMA Exposure on Emergence Latency 
Figure 5 shows the effect of repeated MDMA (0.0, 3.3mg/kg) exposure on 
day 1, and 5 in home cages on emergence latency following MDMA (0.0, 
3.3mg/kg) administration on day 9. A 1-Way ANOVA revealed no significant 
effect of repeated exposure to daily MDMA (3.3mg/kg) injections on emergence 
latency following MDMA (0.0, 3.3mg/kg) administration (F(1,22) = .416, p > 
.05).  
0
5
10
15
20
0.00 3.30
MDMA Dose (mg/kg)
Em
er
ge
n
ce
 
La
te
n
cy
 
(m
in
) ) 0.00 mg/kg3.30 mg/kg
(8) (8)
(8)(8)
MDMA Dose
in Home Cage 
 
Figure 5 Effect of repeated exposure to MDMA (0.0, 3.3mg/kg, IP) on Day 1 
and 5 in home cages on emergence latency (min) following MDMA (0.0, 
3.3mg/kg) administration on Day 9. 
 
Effects of Handling on Emergence Latency 
Figure 6 shows the effect of repeated handling on emergence latency following 
MDMA (0.0, 3.3mg/kg) administration. A 2-Way ANOVA (handling X MDMA 
dose) revealed no significant interaction of repeated handling on emergence 
latency following MDMA (0.0, 3.3mg/kg) administration (F(1,39) = .02, p > .05).  
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Figure 6 Effect of repeated handling on Day 1 and 5 in home cages on 
emergence latency (min) following MDMA (0.0, 3.3mg/kg) administration on 
Day 9.  
 
Discussion 
The present study determined some parameters for use of the Emergence 
Test (ET) as a behavioural assay to examine the acute effects of MDMA. In line 
with similar studies (Callaway et al., 1990; Kehne et al., 1996; McCreary et al., 
1999; Spanos & Yamamoto, 1989) MDMA produced a dose dependent increase 
in locomotor activity (Figure 2). To ensure that behaviour in the ET following 
MDMA administration was not a reflection of hyperactivity, the highest dose of 
MDMA (3.3mg/kg) that had no effect on locomotion was used for establishing 
further protocols in the ET. Some previous studies report an increase in locomotor 
activity following an MDMA dose 3.0mg/kg (McCreary et al., 1999). In the 
current experiment, however, no increase in activity following MDMA 3.3mg/kg 
dose was found. The discrepancy between studies may be due to varying 
methodological procedures. Habituation periods have been shown to alter 
subsequent levels of activity in response to drugs. In well habituated animals 
locomotor activity increases compared to less well habituated animals (Evenden 
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& Angeby-Moller, 1990). McCreary et al. (1999) habituated rats for 3 hours on 
the two days preceding the test in addition to 60 min on the day of the test. In the 
present study habituation was substantially less with only 30minutes on the test 
day. The reduced level of habituation in the present study may therefore account 
for the lack of hyperactivity produced by MDMA (3.3mg/kg).  Additionally, the 
use of different MDMA isomers may have contributed to the varying results. The 
(+) MDMA isomer, as used by McCreary et al. (1999), increases synaptic DA to a 
greater extent than the (+/-) isomer used in the present study (Johnson et al., 1986; 
Hiramatsu & Cho, 1990) and is therefore likely to increase activity to a greater 
extent (Paulus & Geyer, 1992; Fantegrossi et al., 2003).  
Following various habituation periods increases in emergence latency 
were found. A 30minute habituation produced maximal effects of MDMA, 
significantly increasing latencies, and so this habituation period was utilised for 
further ET development.  
Once the MDMA dose (3.3mg/kg) and habituation period (30min) were 
established the effect of repeated exposure to the test environment was measured 
in order to determine whether animals previously exposed to the environment 
were able to be retested. Emergence latency induced by the novel environment 
(the open test arena) was influenced by repeated exposure. Once the animals had 
been exposed to the test arena the tendency to explore was reduced, as has 
previously been demonstrated (File, 1990; File et al., 1990; File et al., 1993). 
Whether this was a response to the loss of novelty of the test or a reflection of 
repeated drug exposure or handling was also explored. When animals were 
repeatedly injected with either MDMA (3.3mg/kg) or saline in home cages, but 
not exposed to the test environment, emergence latencies were unaltered. 
Additionally, handling over several days failed to alter latencies. This suggests 
that in the ET the novelty of the environment is not affected by handling or 
repeated MDMA administration as carried out in this study but, by prior test 
exposure. Accordingly, in the ET future experiments in this thesis will administer 
MDMA (3.3mg/kg) following a 30minute habituation period using a between-
subjects procedure.  
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The emergence latencies of the saline pretreated animals in these 
experiments indicated that, in line with the concept of “neotic” behaviour the 
animals readily explored a novel environment following a period of habituation.  
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Section 2: Emergence Latency (EL) following MDMA Exposure  
Overview 
The aim of the present study was to establish whether tolerance to MDMA 
is associated with changes in 5-HT2c or 5-HT2a receptor responses and /or 
alternatively, an impaired ability of MDMA to evoke SERT-mediated 5-HT 
release. Effects of MDMA, m-CPP, DOI, and fenfluramine were measured using 
an emergence test as in section 1 (Pare et al., 2001).  
DOI is a preferential 5-HT2a receptor agonist (Kleven et al., 1997; 
Schreiber et al., 1995; Willins & Meltzer, 1997) and was therefore used to assess 
the contribution of this receptor subtype to the emergence response. Additional 
testing with the preferential  5-HT2C receptor agonist, m-CPP, and with MDMA 
were also conducted and the specific role of the 5-HT2C receptor in the response to 
MDMA and m-CPP(Bilkei-Gorzo et al., 1998) was determined by measuring the 
effect of the selective receptor antagonist, RS102221 (Bonhaus et al., 1997). 
Fenfluramine was used as a 5HT releasing stimulant (Fuxe, Farnebo, Hamberger, 
& Ogren, 1975; Garattini, Buczko, Jori, & Samanin, 1975) to determine the effect 
of alterations in this mechanism on emergence latency.  Finally, the effect of a 
regimen consisting of repeated exposure to MDMA that decreased brain tissue 
levels of 5-HT on the behavioural response to MDMA, m-CPP and fenfluramine 
was measured (Shankaran & Gudelsky, 1999).  
 
Effects of MDMA, m-CPP, DOI and fenfluramine on EL 
The effect of m-CPP (0.0, 0.3, 0.6 or 1.25 mg/kg, IP), MDMA (0.0, 1.0 
or 3.3 mg/kg, IP), fenfluramine (0.0, 1.0, or 2.0 mg/kg, IP), and DOI (0.0, 1.0, 2.0 
mg/kg, IP) on EL was assessed in separate groups of randomly assigned rats. 
Immediately following administration of the drugs the rats were placed into the 
hide box for 30 (MDMA), 15 (m-CPP, fenfluramine) or 10 (DOI) minutes. These 
treatment times were chosen based on preliminary studies that examined the time 
course of the effect of the four drugs. Following the habituation period, the slide 
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door was opened and latency to emerge was measured. Rats that failed to emerge 
within 30 minutes were removed and a score of 30 min was assigned.  
Effects of 5-HT2C receptor antagonist pretreatment on MDMA, m-CPP and 
fenfluramine EL 
The effect of the selective 5-HT2C receptor antagonist, RS102221 (0.0, 
0.25, 0.5 or 1.0 mg/kg, IP) on m-CPP- (1.25 mg/kg) and MDMA-(3.3 mg/kg, IP) 
produced increases in EL was subsequently assessed in separate groups of 
randomly assigned rats. These doses of MDMA and m-CPP were chosen because 
they produced increased EL without significant changes in locomotor activity 
(Brennan & Schenk, 2006). Preliminary studies indicated that maximal effects of 
RS102221 were produced 15 min following injection. Therefore, the hide box was 
opened 15 min following the injection of RS102221. To allow peak times of 
agonist and antagonist to coincide, m-CPP and RS102221 were administered 
simultaneously, whilst MDMA was administered 15 min prior to RS102221. 
Effects of MDMA pre-treatment on  MDMA, m-CPP and fenfluramine EL  
Two weeks prior to testing separate groups of rats received MDMA (10.0 
mg/kg per injection, IP) pretreatment or the saline vehicle, as inidicated in 
General Methods. On test day, effects of m-CPP (0.0 or 1.25 mg), MDMA (0.0 or 
3.3 mg/kg), and fenfluramine (0.0 or 2.0 mg/kg) on EL was measured as above. 
The doses of MDMA, m-CPP and fenfluramine were chosen as preliminary 
studies found that they produced increased EL without alterations to locomotor 
activity. Other groups of rats were treated with saline or MDMA as above and two 
weeks later brain 5-HT and 5-HIAA tissue levels were measured.  
Results 
Effects of MDMA, m-CPP, DOI and fenfluramine on EL 
All drugs increased EL except for DOI (m-CPP: (F(3,28)=8.73, p< 0.05, 
Figure 7); MDMA: (F(2,45)=67.17, p< 0.05, Figure 8); fenfluramine: (F(2, 23)= 
7.35, p< 0.05, Figure 9 ); DOI: (F(2, 15)= 1.09, NS, Figure 10).  
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Figure 7 Effect of m-CPP (0.00, 0.30, 0.60, 1.25 mg/kg, IP) on emergence 
latency (+SEM). Significant difference relative to control group * p<.05. 
 
0
5
10
15
20
25
30
0.00 1.00 3.30
MDMA Dose (mg/kg) 
Em
er
ge
n
ce
 
La
te
n
cy
 
(m
in
) )
(16)
 (16)
 (16)
*
 
Figure 8 Effect of MDMA (0.0, 1.00, 3.30 mg/kg, IP) on emergence latency 
(+SEM). Significant difference relative to control group * p<.05. 
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Figure 9 Effect of fenfluramine (0.0, 1.00, 2.00 mg/kg, IP) on emergence 
latency (+SEM). Significant difference relative to control group * p<.05. 
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Figure 10 Effect of DOI (0.0, 1.00, 2.00 mg/kg, IP) on emergence latency 
(+SEM).  
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Effects of 5-HT2C receptor antagonist pretreatment on MDMA and m-CPP EL 
Figure 11 shows the effect of the 5-HT2C receptor antagonist, RS102221, 
on m-CPP- (Figure 11A) and MDMA- (Figure 11B) produced increased EL. 
RS102221 dose-dependently attenuated the increased EL produced by both m-
CPP (F(3,60)=4.116, p<0.05) and MDMA (F(3,28)=5.427, p<0.01). Post-hoc tests 
indicated that the highest dose of RS102221 significantly reduced the effect of 
both m-CPP and MDMA. The lower dose of 0.5 mg/kg also attenuated the 
MDMA-produced effect (p< 0.05). 
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Figure 11 Effect of RS102221 pretreatment on m-CPP (1.25mg/kg, IP) 
(Figure 11A) and MDMA (3.3mg/kg, IP) (Figure 11B) increased emergence 
latency (+SEM). Significant difference relative to control group * p<.05. 
 
Effects of MDMA pre-treatment on  MDMA, m-CPP and fenfluramine EL  
Figure 12 shows the effect of MDMA pre-treatment on the increase in 
EL produced by m-CPP, MDMA, and fenfluramine. MDMA pre-treatment failed 
to alter the acute effect of m-CPP (F(1,14)=.328, p >0.05) but significantly 
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attenuated MDMA (F(1,25) =33.452, p<0.01) and fenfluramine (F(1,17)= 16.26, 
p<0.05) produced increases in EL. 
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Figure 12 Effect of saline or MDMA pretreatment on m-CPP (1.25mg/kg, IP), 
MDMA (3.3mg/kg, IP) and fenfluramine (2.00mg/kg, IP) produced increases 
in emergence latency. Significant difference relative to control group * p<.05. 
 
 
Effects of MDMA pre-treatment on brain 5-HT and5-HIAA tissue concentrations  
Effects of MDMA pre-treatment on tissue levels of 5-HT and 5-HIAA 
are shown in Table 1. 5-HT and 5-HIAA levels were significantly lower in 
MDMA pre-treated rats in all brain regions assayed (striatum: 5-HT (F(1,9)=5.249, 
p< 0.05), 5-HIAA (F(1,9)=7.03, p< 0.05); frontal cortex 5-HT (F(1,9)=13.98, p< 
0.01), 5-HIAA (F(1,9)=10.78, p< 0.01); hypothalamus 5-HT (F(1,9)=25.14, p< 
0.01), 5-HIAA (F(1,9)=7.92, p< 0.05); and hippocampus 5-HT (F(1,9)=6.49, p< 
0.05), 5-HIAA (F(1,9)=45.06, p< 0.01). 
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Table 1 Tissue levels (ng/mg) of 5-HT and 5-HIAA 2 weeks following MDMA 
or vehicle pre-treatment (n=6 per group) (+SEM). Significance relative to 
control groups * p< 0.05 or ** p< 0.01. 
 5-HT 5-HIAA 
 Control MDMA Control MDMA 
 
Brain Region     
Frontal Cortex .344±.02 .233±.01** .302±.01 .232±.01** 
Striatum .403± .03 .302±.02* .630± .01 .569±.01* 
Hippocampus .563±.04 .435±.02* .564±.02 .377±.01** 
Hypothalamus 1.15±.03 .917±.03** .829±.07 .600±.04* 
 
 
 
Discussion 
Acute exposure to m-CPP, MDMA, and fenfluramine increased the 
latency to emerge into a novel environment, as has previously been reported 
(Bilkei-Gorzo et al., 1998; Morley, Arnold, & McGregor, 2005) but DOI failed to 
alter EL. The lack of a DOI-produced effect on EL is in contrast to the decrease in 
open arm exploration on the elevated plus maze found by Bull and colleagues 
(Morley et al., 2005). The doses of DOI used in the present study produced 5-
HT2a receptor-mediated behaviours such as wet dog shakes (Kleven et al., 1997; 
Schreiber et al., 1995; Willins & Meltzer, 1997) supporting the idea that they were 
behaviourally relevant. The failure of DOI to produce an effect on EL suggests a 
limited role of the 5-HT2a receptor subtype in this behaviour. The increased EL 
produced by m-CPP and MDMA was, however, attenuated by the selective 5-
HT2c receptor antagonist, RS102221, suggesting an important role of this receptor 
subtype in these drug-produced responses.  
The 5-HT2c receptor was previously reported to play a minimal role in 
MDMA produced increase in EL. Specifically, pre-treatment with the 5-HT2c/b 
receptor antagonist, SB 206553 (2 mg/kg), failed to block the increase in EL 
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produced by MDMA (Morley et al., 2005). The long antagonist pre-treatment 
time employed and use of only a single dose of SB 206553 might have precluded 
observation of an effect. Alternatively, the non-selectivity of SB 206553 for the 5-
HT2c receptor might also have limited observation of an effect (Grignaschi et al., 
1998; Kennett et al., 1996). 
A concern with this type of study is that EL can be confounded by drug-
produced alterations in locomotor activity. Because the EL requires movement 
from one location to another, drugs that alter baseline locomotor activity might 
produce a non-specific change in EL. Accordingly, the increased EL produced 
following m-CPP, fenfluramine or MDMA administration might reflect the well 
documented decrease in locomotor activity produced by serotonergic agonists 
(Gleason, Lucaites, Shannon, Nelson, & Leander, 2001; Lucki, Ward, & Frazer, 
1989; Martin et al., 1998). In the present study, however, doses of all three 
compounds that increased EL were less than those required to produce a 
generalised decrease in motor activity (unpublished findings). Therefore, the 
increased EL cannot easily be attributed to non specific effects.  
In contrast to results of other studies, MDMA pre-treatment did not alter 
baseline exploratory behaviour in the present study. Other studies have shown 
increased basal levels of exploratory behaviour in an open field (Mechan et al., 
2002b) or elevated plus maze (Mechan et al., 2002b; Piper & Meyer, 2004) in 
MDMA pre-exposed rats. Importantly, a previous study suggested that MDMA 
pre-treatment decreased basal levels of exploratory behaviour in the emergence 
test (McGregor et al., 2003). The discrepancy between the present findings and 
those of McGregor et al. (2003) might be due to methodological differences 
between the two studies as well as rat strain. Indeed, there is evidence to show 
that Sprague Dawley rats might be more resilient to MDMA exposure than the 
Wistar strain used in the McGregor study (Pare et al., 2001).  
Two weeks following an MDMA pretreatment regimen that significantly 
reduced 5-HT and 5-HIAA levels, m-CPP produced increased EL was unaltered. 
In contrast, tolerance to the effect of MDMA was produced. Because of the 
important role of 5-HT2C receptors in the acute effects of both drugs, the 
differential response to repeated MDMA exposure suggests that tolerance to this 
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behavioural effect of MDMA is not mediated by altered sensitivity of 5-HT2c 
receptors.  Rather, the present data are consistent with the idea that decreased 5-
HT release underlies tolerance to the effect of MDMA (Baumann et al., 2008; 
Shankaran & Gudelsky, 1999).  
Tolerance to MDMA and fenfluramine but not m-CPP might be explained 
by the differential pharmacology of these compounds. MDMA (Green et al., 
2003), m-CPP (Pettibone & Williams, 1984), and fenfluramine (Berger et al., 
1992) are all 5-HT releasing stimulants that elevate synaptic levels via a SERT-
dependent mechanism (Berger et al., 1992; Rudnick & Wall, 1992), and therefore 
indirectly activate 5-HT receptors that have relatively low affinity for 5-HT, 
including the 5-HT2c receptor (Zifa & Fillion, 1992). Repeated exposure to 
MDMA decreased tissue levels of 5-HT (Table 1), reduced SERT binding 
densities (Schenk et al., 2007) and reduced MDMA-produced increases in 
synaptic levels of 5-HT (Shankaran & Gudelsky, 1999). Since SERT-mediated 5-
HT release is the predominant mechanism underlying the response to both 
MDMA and fenfluramine, decreased ability of MDMA and fenfluramine to 
enhance synaptic 5-HT after MDMA pre-treatment would have led to decreased 
activation of the low affinity 5-HT2c receptors.  However, m-CPP is also a direct 
5-HT2c receptor agonist. Therefore, repeated exposure to MDMA would not be 
expected to impact on the ability of this drug to exert its effects in the absence of 
SERT-mediated 5-HT release. Thus, effects of m-CPP are not altered by prior 
exposure to MDMA because of its direct agonist activity at the 5-HT2c receptor. 
Taken together, the data suggest that MDMA-produced tolerance in the 
emergence test is due to impaired 5-HT release. 
The present results indicate that the 5-HT2c receptors associated with 
exploratory behaviour do not become desensitised following MDMA pre-
treatment, as previously suggested (Bull et al., 2003). They extend those findings 
by showing that tolerance to this behavioural effect of MDMA cannot be 
explained by 5-HT2c receptor desensitisation. Rather, the data are consistent with 
the idea that tolerance to MDMA reflects impaired 5-HT release. 
Just as the ET was identified as the most reliable behavioural assay to 
assess the contribution of the 5-HT2a/c receptors in MDMA-induced behaviours 
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future studies will utilise a combination of physiological and behavioural assays 
thought to best elucidate the functional status of 5-HT receptors identified to be 
involved in 5-HT transmission.  
  
63 
Section 3: 5-HT1a functional status following MDMA Exposure 
Overview 
Previous experiments have suggested that tolerance to the effects of acute 
MDMA following MDMA pretreatment may be attributed to impaired 5-HT 
release. As the 5-HT1a autoreceptor is known to play a major role in 5-HT release 
in both the DRN and terminal regions of the DRN projections (Blier et al., 1998), 
the functional status of the 5-HT1a receptor following MDMA pre-treatment was 
investigated.  
Central 5-HT1a receptors are located both within the raphe nuclei of the 
brain stem and terminal regions (Verge et al., 1986). Within the raphe nuclei the 
5-HT1a receptor is an inhibitory somadendritic autoreceptor while is 
predominantly post synaptic in 5-HT terminal fields such as the hippocampus and 
frontal cortex (Aguirre et al., 1998). One function of the 5-HT1a receptor is 
modulation of temperature. Indeed, hypothermia is a common consequence of 
agonist administration (Hedlund et al., 2004; Hillegaart, 1991; Kitamura et al., 
2007). Therefore, the hypothermic response to MDMA following repeated 
MDMA exposure was identified as a reliable measure of 5-HT1a receptor status 
and was utilised to this end. 
The location of the receptors involved in the hypothermic response to 8-
OHDPAT in rats remains equivocal. Some studies suggest that the response is 
mediated by postsynaptic activation (Aguirre et al., 1998; Blier, Seletti, Gilbert, 
Young, & Benkelfat, 2002). For example, one week after a single administration 
of MDMA (30 mg/kg, IP) the hypothermic response to 8-OHDPAT (1 mg/kg, SC) 
was potentiated. This was associated with increased 5-HT1a density in the 
hypothalamus suggesting a postsynaptic contribution (Aguirre et al., 1998). Other 
studies suggest that the response is mediated by a presynaptic mechanism 
(Cowen, Power, Ware, & Anderson, 1994; Young, MacDonald, St John, Dick, & 
Goodwin, 1992) as direct application of 8-OHDPAT into the DRN produced 
hypothermia that was blocked by selective 5-HT1a antagonists (Higgins, 
Bradbury, Jones, & Oakley, 1988; Hillegaart, 1991). These discrepancies may be 
partly due to variations in the dose of the agonist used. Low doses of 8-OHDPAT 
  
64 
(≤ 0.05mg/kg, IP) preferentially activate the autoreceptor while higher doses 
stimulate both pre and postsynaptic receptors (Barnes & Sharp, 1999; Hoyer et al., 
2002).  
The 5-HT1a agonist, 8-OHDPAT, has been extensively used to investigate 
the functional status of the 5-HT1a receptor. 8-OHDPAT is a potent selective 5-
HT1a agonist that induces hypothermia in mice and rats (Hillegaart, 1991; Hjorth, 
1985; Moser, 1991; Renoir et al., 2008). Behavioural, neurochemical, 
electrophysiological and radioligand studies confirm that 8-OHDPAT binds dose 
dependently to both pre and post synaptic 5-HT1a brain sites and can be used to 
investigate the behavioural and pharmacological properties of these receptors 
(Gozlan et al., 1983; Hjorth, 1985; Kennett, Marcou, Dourish, & Curzon, 1987). 
Accordingly, the hypothermic response induced by 8-OHDPAT, was used to 
assess the sensitivity of the 5-HT1a autoreceptor following MDMA pretreatment.  
 
Effects of MDMA Pretreatment on Rectal Temperature 
Separate groups of rats were administered the MDMA pre-treatment 
regime. Two weeks later baseline core body temperatures were recorded. Fifteen 
minutes later various doses of 8-OHDPAT (0.0, 0.0315, 0.0625, 0.125, 0.25, 
0.5mg/kg, SC) were administered and temperatures were recorded 30 min post 
injection. 
 
Results 
Figure 13 shows the effect of MDMA pre-treatment on core body 
temperature and effects of 8-OHDPAT (0.0, 0.0315, 0.0625, 0.125, 0.25, 
0.5mg/kg, SC) injection. A 2-Way ANOVA (MDMA pre-treatment X 8-
OHDPAT dose) revealed a main effect of MDMA pre-treatment (F(1,59) = 20.15, 
p<.01), and 8-OHDPAT dose (F(5,59) = 72.52, p<.01). Post hoc analysis showed 
that the 0.0625, 0.125, 0.25, 0.5mg/kg doses of 8-OHDPAT significantly 
decreased body temperature. A 1-Way ANOVA revealed that MDMA pre-
treatment resulted in  a significantly greater hypothermic response in MDMA pre-
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treated rats at 8-OHDPAT doses 0.0315 (F(1,10)= 18.175, p< .05) and 
0.0625mg/kg (F(1,10)= 6.30, p<.05). 
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Fig 13 Temperature change (deg C) (+SEM) in saline and MDMA pre-
treated rats 30 minutes post acute 8-OHDPAT (0.0, 0.0315, 0.0625, 0.125, 
0.25, 0.5mg/kg, SC) administration. Significant difference relative to saline 
pre-treatment group * p<.05. 
 
Discussion 
Results from the present study indicate that the hypothermic response 
induced by 8-OHDPAT administration was enhanced following MDMA pre-
treatment. Doses of 8-OHDPAT have been shown to distinguish pre and 
postsynaptic activation (Hillegaart, 1991) with low doses (<0.05mg/kg) 
predominately presynaptic and higher doses postsynaptic.  Most importantly, the 
potentiated response following MDMA pretreatment suggests an increased 
sensitivity of the 5-HT1a autoreceptor. This may indicate that 5-HT1a autoreceptor 
efficacy to negatively control 5-HT transmission is enhanced in MDMA 
pretreated rats. While the molecular mechanisms involved in the sensitisation 
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process following MDMA exposure observed in the present study are unclear it is 
possible that the increased sensitivity of the 5-HT1a autoreceptor contributes to the 
deficits in synthesis and release of 5HT that results from MDMA exposure 
(Esteban, Moranta, Sastre-Coll, Miralles, & Garcia-Sevilla, 2002; Shankaran & 
Gudelsky, 1999). If so, the 5-HT1a autoreceptor might be a potential target for 
reversing tolerance to MDMA-produced effects.  
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Section 4. Reversal of Tolerance to MDMA effects: Systemic Studies 
Overview 
Section one of this thesis established the Emergence Test (ET) as a 
behavioural assay to examine the acute effects of MDMA. This paradigm was 
then used, in section two to show that tolerance to the behavioural effects of 
MDMA was most likely due to impaired 5-HT release. This section follows by 
examining the effects of MDMA on 5-HT1a autoreceptor function. 
It is well documented that the 5-HT1a autoreceptor modulates 5-HT 
synthesis and release (Stamford et al., 2000). Regulation of 5-HT cell firing has 
also been attributed to the 5-HT1a autoreceptors located in the dorsal raphe nuclei 
(DRN). Local or systemic activation of 5-HT1a autoreceptor by 5-HT (high 
affinity) or by administration of 5-HT1a agonists which induce 5-HT release 
inhibited 5-HT release in the DRN and in forebrain regions innervated by DRN 
(Artigas, Romero, de Montigny, & Blier, 1996; Blier, Serrano, & Scatton, 1990; 
Hervas et al., 1998; Kreiss & Lucki, 1994).  
Section 3 showed a potentiated hypothermic response to low doses of the 
5-HT1a agonist 8-OHDPAT in MDMA pre-treated rats. It was suggested that 
repeated MDMA exposure rendered the 5-HT1a autoreceptor supersensitive. 
Indeed, there is evidence of 5-HT1a autoreceptor supersensitivity following 
chronic administration of a number of drugs of abuse including ethanol, morphine, 
cocaine and MDMA (Cunningham, Paris, & Goeders, 1992; Kelai et al., 2008; 
Kleven et al., 1995; Renoir et al., 2008; Sastre-Coll, Esteban, & Garcia-Sevilla, 
2002).MDMA pretreatment increased 8-OHDPAT -induced hypothermia in mice. 
In vitro, MDMA pretreatment potentiated the inhibition of DRN 5-HT cell firing 
following application of a 5-HT1a agonist (Renoir et al., 2008). Chronic cocaine 
pretreatment also potentiated the inhibitory response of DRN 5-HT neurons to (-)-
cocaine, 8-OHDPAT, and a 5-HT reuptake inhibitor (Cunningham et al., 1992).  
Enhanced behavioural 5-HT1a mediated responses have also been reported. 
For example, chronic ethanol produced an increase in lower lip retraction in 
withdrawn rats, a response that is mediated by the 5-HT1a autoreceptor (Esteban et 
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al., 2002).This hypersensitivity would be expected to enhance the inhibitory 
effects of the 5-HT1a autoreceptor on 5-HT synthesis and release.  
MDMA pretreatment produces long lasting decreases in 5-HT 
neurotransmission (Stone, Hanson, & Gibb, 1989a; White et al., 1996). Following 
pretreatment there is a persistent deficit in tissue levels of 5-HT and 5-HIAA, 
inactivation of tryptophan hydroxylase (TPH), loss of SERT binding and function, 
and alterations in 5-HT1a density (Aguirre et al., 1995; Battaglia et al., 1988; 
Scanzello et al., 1993; White et al., 1996). These deficits, which are most 
pronounced after a short withdrawal period (Battaglia et al., 1987; Reneman et al., 
2002) have been shown to persist for more than a year depending on MDMA dose 
and brain region assayed.  In vitro, reactivation of central TPH through anaerobic 
incubation was dependent on MDMA dose and the period of time following 
exposure. Higher MDMA doses and longer periods post exposure decreased the 
ability to restore TPH activity and ultimately 5-HT synthesis (Stone, et al., 1989a; 
Stone et al., 1989b).  
Many of the deficits in 5-HT function following MDMA exposure maybe 
due, in part, to the resulting supersensitivity of the 5-HT1a autoreceptor. A 
supersensitive 5-HT1a autoreceptor would result in enhanced inhibition of 
tryptophan hydroxylase thereby leading to persistent 5-HT and 5-HIAA 
depletions. This in turn would result in less 5-HT release when the system is 
challenged with a resultant reduction in the activation of 5-HT receptors that 
contribute to the effects of MDMA. Together, these may explain tolerance to 
some of MDMA-produced effects. If so, then a desensitisation of the 5-HT1a 
autoreceptor would reduce its inhibitory actions leading to a recovery of 5-HT 
synthesis. One means of desensitising the autoreceptor is through the repeated 
administration of a highly selective 5-HT1a antagonist. 
The selective 5-HT1a antagonist, WAY100635, is classed as a silent 
agonist because it lacks any agonist properties at pre or post synaptic sites. In vivo, 
WAY100635 dose-dependently blocked the ability of 8-OHDPAT to inhibit the 
firing of dorsal raphe 5-HT neurons and to induce 5-HT postsynaptic receptor 
mediated behaviours including 5-HT syndrome and hyperphagia (Fletcher et al., 
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1996).WAY100635 is >100-fold more selective for 5-HT1a than any other 5-HTor 
DA receptors or reuptake sites (Fletcher et al., 1996).  
Several studies have administered WAY100635 to ascertain that the 
effects of 5-HT1a agonists are due to 5-HT1a mechanisms. WAY100635 (1.0mg/kg, 
SC) administered to guinea pigs alone produced no observable behaviours 
(Mundey, Fletcher, & Marsden, 1996; Roberts, Boyd, Middlemiss, & Routledge, 
1999) but it fully blocked 8-OHDPAT induced behaviours. It was suggested that 
this was due to competitive antagonism by WAY100635 of somadendritic 
autoreceptors in the DRN via the negative feedback loop. When administered 
together with 8-OHDPAT, WAY100635 blocked 8-OHDPAT produced inhibition 
of cell firing, again suggesting that the DRN 5-HT tone is modulated by an 
inhibitory 5-HT1a autoreceptor.  
By repeatedly blocking the 5-HT1a autoreceptor the inhibitory influence on 
neuronal firing and activity in the raphe would be reduced and consequently 5-HT 
synthesis and release may be enhanced. Indeed, WAY100635 (0.125-.5mg/kg, IV) 
increased the firing rate of DRN neurons. Of interest, WAY100635 alone restored 
DRN firing that was previously inhibited by 8-OHDPAT. These findings suggest 
that WAY100635 may be used to alter the sensitivity of the 5-HT1a autoreceptor. 
An effect of WAY100635 on 5-HT release has also been shown using in vivo 
microdialysis. Roberts et al. (1999) found that WAY100635 elicited small 
increases in extracellular levels of 5-HT in the frontal cortex. Repeated 14 day 
WAY100635 pretreatment failed to alter basal levels of 5-HT in the hippocampus 
(Gurling, Ashworth-Preece, Dourish, & Routledge, 1994) but a 7 day pretreatment 
increased 5-HT synthesis in the DRN (Tohyama, Yamane, Merid & Diksic, 2001). 
These studies suggest that pretreatment period might be critical to the effects of 
WAY100635.   
Section 4 tests the possibility that behavioural tolerance following 
repeated MDMA exposure can be reversed by repeated exposure to WAY100635. 
Because 5-HT1a receptors have been implicated in feeding (Dourish et al., 1985; 
Fletcher et al., 1996) food consumption following the chronic 7 day 5-HT1a 
antagonist, WAY100635, administration was also measured.  
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In order to measure the functional response following WAY100635 
administration locomotor activity was chosen as the behavioural assay. Tolerance 
to MDMA-produced hyperactivity has consistently been reported (Brennan & 
Schenk, 2006; Callaway & Geyer, 1992) and this assay allows for the time-course 
of the behavioural effects of MDMA. The effect of MDMA pretreatment on 
MDMA-produced hyperactivity was established in the current study to determine 
the baselines from which 5-HT1a antagonist application could be investigated.  
Tissue levels of 5-HT and 5-HIAA were measured in order to verify that 
the MDMA pretreatment regimen used in the present study produced deficits of 5-
HT as has previously been reported (Shankaran & Gudelsky, 1999) and to 
determine any effects of WAY100635 pretreatment.  
 
Procedures: 5-HT1a antagonist WAY100635 7 day Chronic Subcutaneous Regime 
 On day one rats were pre-treated as per the MDMA pre-treatment regime. 
Seven days later 7 1x daily injections of either WAY100635 (0.0, 0.01, 0.1, 
1.0mg/kg per injection, SC) or saline vehicle were administered. This 
pretreatment procedure was in line with Tohyama et al. (2001) who reported 
increases in DRN 5-HT synthesis following chronic WAY100635 administration 
as determined by autoradiography. Two weeks following the MDMA pre-
treatment rats were behaviourally assessed with an MDMA (10.0mg/kg, IP) or 
vehicle challenge. Two days later animals were euthanized and brains removed 
(see Figure 3). 
The schedule of the WAY100635 chronic subcutaneous administration 
experiments is shown in Figure 14. 
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Fig 14 Schematic diagram of experiments outlining MDMA pretreatment, 5-
HT1a antagonist, WAY100635 (0.00, 0.01, 0.10, 1.0mg/kg, SC) pretreatment, 
MDMA (0.0, 10.0mg/kg, IP) administration, behavioural testing and brain 
removal for 5-HT and 5-HIAA HPLC analysis. 
 
Food consumption  
Food consumption was measured following the first and last daily injection of 
WAY100635 administration. 
Effects of MDMA Pretreatment on MDMA -induced Hyperactivity  
Effects of MDMA Pre-treatment on MDMA-Produced Hyperactivity  
MDMA and saline pretreated rats were administered the MDMA pre-
treatment regimen as in General Methods. On the test day, the rats were placed in 
the activity boxes for 30minutes after which they received an injection of MDMA 
(0.0 or 10.0 mg/kg, IP) and locomotor activity was recorded for a further 
60minutes. 
 
 
Day 1 Day 7  Day 14  Day 16  
MDMA 
Pre-
treatment 
7x daily sc 
WAY100635 
injections 
MDMA 
Challenge + 
Beh test 
Brains 
removed  
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Effects of WAY100635 pretreatment on MDMA-induced Hyperactivity  
Effects of WAY100635 Treatment Following Saline and MDMA Pretreatment on 
MDMA-Induced Hyperactivity  
Groups of saline and MDMA pre-treated rats were used to test the effects 
of 7 daily injections of WAY100635 (0.0, 0.01, 0.1, 1.0 mg/kg, SC) on MDMA 
(0.0, 10.0mg/kg IP) produced hyperactivity. Activity was recorded, as above, 24 
hr after the last WAY100635 injection. This withdrawal period was chosen so that 
any behavioural response assessed neuroadaptive changes rather than acute drug 
effects (Fletcher et al., 1996). 
 
Table 2 Drug conditions defined by MDMA pretreatment, chronic WAY100635 
and acute MDMA drug administration 
Conditions Pretreat Chronic 
Administration 
Acute 
Administration 
SSS Saline Saline Saline 
SWS Saline WAY100635 Saline 
MSS MDMA (40mg/kg) Saline Saline 
MWS MDMA (40mg/kg) WAY100635 Saline 
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Results 
Food Consumption following WAY100635 Administration 
Figure 15 shows the food consumption of rats following the first and last 
day of WAY100635 (1.0mg/kg, SC) administration.  A 2-Way ANOVA (days X 
WAY100635) with days as a repeated measure revealed no significant interaction 
between these factors (F(1,46)=1.89, p>.05). There was no main effect of day 
(F(1,46)= 1.89, p>.05) or WAY100635 pretreatment (F(1,46)=.01,p>.05) 
indicating that WAY100635 had no influence on food consumption.  
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Figure 15 Mean food consumption (gms) following the first and last daily 
WAY100635 (0.0, 1.0mg/kg, SC) injection in vehicle and MDMA Pre-treated 
rats (+SEM). 
 
Effect of MDMA Pre-treatment on MDMA-Produced Hyperactivity 
Figure 16 shows the time course of activity counts in the 60 minute period 
post acute MDMA (0.0, 10.0mg/kg) in saline and MDMA-pre-treated rats (Figure 
16A). A 3 -Way ANOVA (time X pre-treatment X MDMA dose) revealed no 
significant interaction between these factors (F(11,275) =.67, p> .05). There was a 
main effect of MDMA dose (F(1,25)=106.52, p<.05) and pre-treatment (F(1,25) = 
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5.86, p< .05). Figure 16B shows the total number of activity counts in the 60 
minute period post acute MDMA (0.0, 10.0mg/kg) in saline and MDMA-pre-
treated rats. A 2-Way ANOVA (MDMA dose X pre-treatment) revealed a 
significant interaction between these factors (F(1,25) = 5.56, p< .05) as well as 
main effects of MDMA dose (F(1,25) = 106.52, p< .001) and pre-treatment 
(F(1,25) = 5.861, p< .05). A 1-Way ANOVA for MDMA dose (10.0mg/kg) in 
saline and pretreated animals revealed a significant difference (F(1,15)= 8.13, 
p<.05) with MDMA pretreatment reducing MDMA-produced hyperactivity. 
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Figure 16 Activity counts produced following MDMA (0.00, 10.0 mg/kg, IP) 
administration in saline and MDMA pretreated rats. The top panel (Figure 
16A) shows the time course of the mean activity counts produced following 
MDMA (0.0, 10.0mg/kg, IP at time =0) administration 2 weeks following 
saline or MDMA pretreatment (+SEM) while the bottom panel (Figure 16B) 
shows the total activity counts produced in the 60 minute period post MDMA 
(0.0, 10.0mg/kg, IP) administration following saline or MDMA pretreatment. 
Significant difference relative to saline pre-treatment group * p<.05. 
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Effects of WAY100635 administration on MDMA-induced Hyperactivity 
following Saline and MDMA pretreatment  
 
Figure 17 shows the time course of MDMA -produced hyperactivity 
following WAY100635 (0.0, 0.01, 0.1, 1.0mg/kg, SC) 7 day chronic 
administration in saline pretreated rats (Figure 17A).A 3-Way ANOVA (WAY 
pretreat X MDMA dose X time) with time as a repeated measure revealed no 
interaction between these factors (F(33,495) = .43, p>.05). There was an 
interaction between WAY100635 and MDMA dose (F(3,45) = 3.89, p<.05). 1-
Way ANOVAs (WAY dose X time) with time as repeated measure revealed a 
main effect of WAY100635 following MDMA (10.0mg/kg) administration 
(F(3,25) =4.94, p<.05) but not following saline (F(3,20) =.30, p>.05). Post hoc 
analysis revealed that WAY100635 doses 0.1 and 1.0mg/kg significantly 
attenuated MDMA-induced hyperactivity.  
Figure 17 B shows the total activity counts produced by acute MDMA (0.0, 
10.0mg/kg) following various doses of the 7 day chronic WAY100635 (0.0, 0.01, 
0.1, 1.0mg/kg, SC) administration in saline pretreated rats. A 2-Way-ANOVA 
(MDMA X WAY100635) revealed a main interaction between these factors 
(F(3,45)=3.89, p<.05). There was a main effect of MDMA dose (F(1,45)=110.99, 
p<.05) with MDMA 10.0mg/kg significantly increasing locomotor activity above 
baseline. There was also a main effect of WAY100635 dose (F(3,4.053)= p<.05). 
A 1-Way ANOVA of WAY100635 dose in MDMA challenged rats revealed a 
main effect of WAY100635 dose (F(3,25)=4.396, p<.05). Post hoc analysis 
showed that WAY100635 doses 1.0mg/kg and 0.1mg/kg significantly attenuated 
MDMA produced hyperactivity. 
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Figure 17 Activity counts produced following MDMA (0.00, 10.0 mg/kg, IP) 
administration in saline pretreated rats. The top panel (Figure 17A) shows 
the time course of the mean activity counts produced by MDMA (0.0, 
10.0mg/kg, IP at time =0) administration following 7 days of chronic 
WAY100635 (0.0, 0.01, 0.1, 1.0mg/kg,SC) pretreatment following saline 
pretreatment (+SEM) while the bottom panel (Figure 17B) shows the total 
activity counts produced in the 60 minute period post MDMA (0.0, 10.0mg/kg, 
IP) in saline pretreated rats following WAY100635 pretreatment. Significant 
difference relative to control group * p<.05. 
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Figure 18 shows the time course for MDMA (0.0, 10.0mg/kg, IP) 
produced hyperactivity following WAY100635 (0.0, 0.01, 0.1, 1.0mg/kg, SC) 7 
day chronic administration in MDMA pretreated rats (Figure 18A). A 3-Way 
ANOVA (WAY pretreat X MDMA dose X time) with time as a repeated measure 
revealed no interaction between these factors (F(22,473) = .58, p>.05). There was 
no interaction between WAY100635 and MDMA dose (F(3,43) = 1.90, p<.05). 
WAY100635 at any dose failed to significantly alter MDMA-induced 
hyperactivity. Figure 18B shows the total activity counts produced by MDMA 
(0.0, 10.0mg/kg) following various doses of the 7 day chronic WAY100635 (0.0, 
0.01, 0.1, 1.0mg/kg) administration in MDMA pre-treated rats. A 1-Way ANOVA 
revealed no main effect of WAY100635 at any dose on MDMA-induced 
hyperactivity in MDMA pretreated rats challenged with MDMA (10.0mg/kg, IP) 
(F(3,28)=2.509, p>.05). 
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Figure 18 Activity counts produced following MDMA (0.00, 10.0 mg/kg, IP) 
administration in MDMA pretreated rats. The top panel (Figure 18A) shows 
the time course of the mean activity counts produced by MDMA (0.0, 
10.0mg/kg, IP at time =0) administration following 7 days of chronic 
WAY100635 (0.0, 0.01, 0.1, 1.0mg/kg, SC) pretreatment following saline 
pretreatment (+SEM) while the bottom panel (Figure 18B) shows the total 
activity counts produced in the 60 minute period post MDMA (0.0, 10.0mg/kg, 
IP) in MDMA pretreated rats following WAY100635 pretreatment. 
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Effect of WAY100635 and MDMA Pre-treatment on brain 5-HT and 5-HIAA 
tissue concentration 
Tissue analysis of brain 5-HT and 5-HIAA concentration following 7 day chronic 
WAY100635 (1.0mg/kg, SC) administration  
Table 3 show the effect of MDMA pre-treatment on brain 5-HT and 5-
HIAA tissue levels. 1-Way ANOVAs revealed a main effect of MDMA 
pretreatment on 5-HT levels in the frontal cortex (F(1,10)=5.78, p<.05) and the 
striatum (F(1,10)=8.99, p<.05). No significant 5-HIAA (F(1,10)=0.00;p>.05); 
(F(1,10)=1.24), p>.05) depletions were found in either region however there was a 
reduction in both regions. As expected in the dorsal raphe MDMA pretreatment 
failed to produce a main effect on 5-HT and 5-HIAA levels (F (1, 10)=.01, p>.05), 
(F(1,10)= 1.19, p>.05).  
1-Way ANOVAs revealed that WAY100635 administration failed to alter 
5-HT and 5-HIAA tissue concentrations in all brain regions (frontal cortex: 
(F(1,8)= 1.995, p>.05), (F(1,8)=.10, p>.05); striatum: (F(1,8)= .311, p>.05), 
(F(1,8)=.05, p>.05); dorsal raphe (F(1,8)= .021, p>.05), (F(1,8)=.52, p>.05) and 
MDMA pretreated rats (frontal cortex: (F(1,8)= .512, p>.05), (F(1,8)= .148, 
p>.05); striatum: (F(1,8)=.002, p>.05), (F(1,8)=.04, p>.05); dorsal raphe 
(F(1,8)= .353, p>.05), (F(1,8)=.49, p>.05). The effects of MDMA pretreatment on 
5-HT levels were not significantly altered by WAY100635 administration. 
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Table 3 HPLC analysis of the frontal cortex, striatum and dorsal raphe 5-HT 
and 5-HIAA tissue levels (ng/mg) following MDMA and WAY100635 
pretreatment. * p<.05 compared to SSS group  
5-HT and 5-HIAA tissue concentration (ng/mg) 
 Frontal Cortex Striatum Dorsal Raphe 
 5-HT 5-HIAA 5-HT 5-HIAA 5-HT 5-HIAA 
SSS .277±.033 .339±.030 .587±.023 .831±.018 1.184±.455 2.074±.632 
SWS .211±.010 .325±.024 .538±.084 .936±.089 1.105±.310 2.711±.612 
MSS .199±.036* .299±.018 .391±.064* .802±.047 1.196±.277 2.707±.360 
MWS .157±.021 .318±.049 .379±.034 .812±.069 .890±.434 2.351±.576 
 
 
 
Discussion 
In the current section chronic administration of WAY100635 did not affect 
feeding in saline or MDMA pretreated rats. An important role for the 5-HT1a 
autoreceptor in feeding has been suggested on the basis of agonist studies 
(Dourish et al., 1985; Fletcher et al., 1996). The antagonist, WAY100635, 
however, failed to alter feeding in this and other studies (Fletcher et al., 1996). 
The present results also suggest repeated 5-HT1a antagonist administration failed 
to influence food intake.   
As previously reported MDMA produced a time dependent increase in 
locomotor activity (Brennan & Schenk, 2006; Callaway & Geyer, 1992). 
Following MDMA pre-treatment, MDMA-induced hyperactivity was attenuated, 
suggesting behavioural tolerance. In line with previous findings, MDMA 
pretreatment significantly decreased 5-HT tissue levels in the frontal cortex and 
striatum. Although 5-HIAA levels reductions in MDMA pretreated rats was not 
significant there was evidence of a reduction in both regions.  
It was reasoned that tolerance reflected a supersensitive 5-HT1a 
autoreceptor and that repeated administration of the antagonist, WAY100635, 
would reverse the deficits. In contrast to this hypothesis, chronic blockade of the 
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5-HT1a receptor significantly reduced MDMA-induced hyperactivity in both 
saline and MDMA pretreated rats. 
 Activation of specific 5-HT1a autoreceptors produced different responses 
that were dependent on brain region. For example, activation of DRN 5-HT1a 
autoreceptors by 8-OHDPAT potentiated cocaine-induced hyperlocomotion but 
MRN activation had no effect (Carey, Depalma, Damianopoulos, Muller, & 
Huston, 2004).Other studies have also found opposite effects of the DRN and 
MRN receptor activation on 5-HT neurotransmission (Hervas et al., 1998; Higgins 
& Elliot, 1991; Hopwood & Stamford, 2001). Therefore, following systemic 
exposure to the antagonist, these region specific effects might serve to cancel or 
mask the other’s response.  
The repeated administration of WAY100635 failed to alter 5-HT tissue 
concentration in all brain regions examined. This is in contrast to Tohyama et al. 
(2001) who reported an increase in DRN 5-HT synthesis following chronic 
WAY100635 administration. This discrepancy may be explained by the varying 
methods of 5-HT measurement. Just as extracellular 5-HT levels measured by 
microdialysis are not directly correlated with 5-HT tissue content (Wang, 
Baumann, Dersch, & Rothman, 2007), autoradiograpghy measurement may not 
correlate with 5-HT tissue levels. This suggests that tissue content does not 
necessarily exclude an increase in 5-HT synthesis or extracellular 5-HT levels 
following WAY100635 chronic administration.  
The aim of the current study was to reverse tolerance to the motor 
activating effects of MDMA and deficits in 5-HT following MDMA pretreatment. 
The idea was that administration of the 5-HT1a antagonist, WAY100635, would 
desensitise the autoreceptor thereby restoring normal levels of synthesis and 
release. The treatment employed, however, failed to reverse the effects.  
There are several possible explanations for the failure to reverse the effects 
of repeated MDMA exposure. Two of these possibilities concern the route of 
WAY100635 administration and the short period of withdrawal following 
WAY100635 pretreatment. Because systemic administration is not selective, 
WAY100635 may have blocked both pre and postsynaptic 5-HT1a receptors. 5-
HT1a receptors are located extensively throughout the CNS and therefore it is 
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likely that many receptors in different brain areas were impacted by the chronic 
treatment. If so, it might not be surprising that the manipulation was ineffective. 
The short withdrawal period following WAY100635 administration does not 
preclude the possibility that the results reflect an acute WAY100635 effect or 
alternatively any reversal or neuroadaptations may only be evident following a 
longer withdrawal period. These possibilities will be addressed in the following 
section. 
Subsequent data from our laboratory has determined that extending the 
withdrawal following subcutaneous administration of WAY1000635 to 7 days 
also failed to impact on tolerance to MDMA-produced hyperactivity. Therefore, 
the next section examined effects of local application of WAY100635 directly 
into the DRN.  
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 Section 5: Reversal of Tolerance to MDMA effects: Intracranial Studies 
Overview 
The inhibitory 5-HT1a autoreceptors are located in the somatodendritic 
region of 5-HT neurons in the raphe nuclei (Gozlan et al., 1983; Verge et al., 
1986). These receptors in the dorsal raphe nucleus (DRN) play a major role in the 
autoregulation of 5-HT synthesis and cell firing (Blier et al., 1990; Casanovas & 
Artigas, 1996). Additionally, the DRN neurons innervate a wide range of cortical 
regions including the striatum and frontal cortex (Hillegaart, 1991). Consequently, 
the DRN has been extensively targeted when investigating 5-HT1a autoreceptor 
modulation.  
As the DRN 5-HT1a autoreceptor modulates CNS 5-HT activity section 5 
will administer WAY100635 directly into the DRN. Preliminary studies suggested 
that a maximum of 4 injections into tissue could be made reliably. The period 
following the last WAY100635 injection will be extended to 3 days as opposed to 
the 24 hour withdrawal period used in the previous experiments. This period may 
better allow the development of neuroadaptive changes. In the literature there is a 
wide range of WAY100635 doses (100ng - 1µg) used for local injections (Cheeta, 
Kenny, & File, 2000; Herges & Taylor, 1999; Marco, Moreno, & de Pablo, 1999). 
The present study used a dose (500ng) for DRN injections that was mid range of 
those previously reported. Levels of 5-HT and 5-HIAA in striatum and frontal 
cortex will be measured to determine any reversal of MDMA-induced deficits by 
WAY100635 pretreatment. 
 
Procedures: WAY100635 4 day Chronic Intracranial-DRN Regime 
 On day one intracranial DRN surgery was performed and the animals 
allowed a minimum of 5 days recovery. Rats were then administered the MDMA 
pre-treatment regime. Seven days following the MDMA pre-treatment regime, 
rats were administered 4 1xdaily intracranial-DRN micro-injections of either 
WAY100635 (at a concentration of 0.5µg/0.5µ1 per injection; 500ng) or saline 
vehicle. Two weeks following the MDMA pre-treatment rats were behaviourally 
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assessed with an MDMA (10.0mg/kg) or vehicle challenge. Animals were 
euthanized two days later and brains removed (see Figure 19). 
 
 
 
 
 
 
 
 
 
 
Figure 19 Schematic diagram of experimental timetable of intracranial 
surgery, MDMA pretreatment, DRN microinjections of WAY100635 (0.00, 
500ng), MDMA (0.0, 10.0mg/kg, IP) administration, behavioural testing and 
brain removal for 5-HT and 5-HIAA HPLC tissue analysis  
 
Intracranial-Dorsal Raphe Nucleus (DRN) Surgery 
For intracranial-DRN surgery rats were anaesthetized intraperitoneally (IP) 
with ketamine/xylazine (90/9 mg/kg) (Phoenix Pharmaceuticals).After visually 
observing that the anaesthesia had taken effect, the rats were given a subcutaneous 
(SC) injection of Carprofen (Pfizer NZ Ltd) (5mg/kg) for pain relief and their 
eyes swabbed with an eye ointment Lacri- Lube (Allergan), to ensure that the eyes 
remained moisturised. To ensure that the rats were deeply anaesthetized, a tail 
pinch was used to illicit a pain reflex. Once the anaesthetic was effective the rats 
were placed in a stereotaxic frame (David Kopf Instruments, South Natick, MA, 
USA) with the incisor bar at 3.3 mm (flat skull position) below the interaural line. 
The skull was exposed by retracting the skin and clearing the area so that the 
bregma and lambda were clearly visible. The stereotaxic instrument was aligned 
above the dorsal raphe nucleus (AP -7.4mm, L 0mm from the Bregma) according 
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to the stereotaxic atlas Paxinos and Watson (2005). A hole (2mm i.d) was drilled 
to expose the dura. The meninges was then scratched with a hooked needle to 
reduce resistance against the guide cannula. A stainless-steel guide cannula (22 
gauge) was implanted, V - 4.8mm from brain surface, so that the tip of the 
cannula was located 1mm above the DRN (see Figure 20). This was held in place 
by three stainless steel screws and dental acrylic cement. Guide cannulae were 
sealed by removable dummy stainless-steel probes to prevent occlusions. Figure 2 
shows the location of the DRN injector. Rats were then injected with 12mls of 
sodium lactate subcutaneously and the pain reliever Carprofen (5mg/kg) to aid 
postoperative recovery. Following the surgical procedure animals were placed on 
a homeothermic heated blanket (Argus Heating Ltd, NZ) until they regained 
consciousness then placed in individual cages to recover.  Animals were allowed a 
minimum of 5-7 days to recover, or until they had regained their pre-operative 
body weight, before any further experimental procedures.  
Intracranial-DRN Micro-injections 
For intracranial-DRN drug injections, an injector (30-gauge) was 
introduced through the guide cannula until its tip extended 1mm beyond the 
cannula tip. A volume of 0.5 µl was injected over a period of 1 minute using a 50 
µl microsyringe with a diameter of 1.46 mm (701-LT, Hamilton, USA) attached 
to a Harvard Apparatus PHD 2000 micro-infusion pump (South Natick, MA, 
USA). The displacement of an air bubble inside the polyethylene catheter 
connecting the syringe needle to the intracranial needle was used to monitor the 
microinjection. At the end of the infusion the injector was left in place for a 
further 1 minute to allow diffusion. 
Histology 
At the completion of the DR micro-injection experiments an intracranial 
injector was inserted through each guide cannula and 0.5 µl of Evans blue was 
injected and the injector removed 1 minute after the injection was finished. This 
was to allow the injection sites to be easily identifiable.   
The animals were asphyxiated by CO², decapitated and the brains rapidly 
removed. The brain was cut on the coronal plane at the level of the optic chiasm. 
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The anterior portion was used for neurochemical analysis. The posterior portion 
was stored at -80° C and cryostat sectioned at 70µm. Slices were mounted and 
stained with neutral red. Placement of the cannulae was verified under a light 
microscope by an independent observer.   
 
 
Figure 20 Coronal section of rat brain showing intracranial dorsal 
raphe injector site according to the stereotaxic atlas Paxinos and Watson 
(2005). 
 
Effects of MDMA Pre-treatment on MDMA-induced hyperactivity  
Separate groups of rats were pre-treated with saline or MDMA regimen 
as in general methods. Two weeks later rats were placed in the activity chambers, 
administered MDMA (0.00, 10.0mg/kg) and tested.  
Effects of WAY100635 on MDMA-induced hyperactivity  
Separate groups of rats were pre-treated with the saline or MDMA 
regimen. Seven days later WAY100635 (0.00, 500ng in 0.5 µl, IC) was 
administered daily for four days. Three days later they were placed in the activity 
chambers and effects on MDMA-produced induced hyperactivity were measured. 
Inject
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Effect of MDMA pretreatment and WAY100635 4 day intra-DRN administration 
on brain 5-HT and 5-HIAA tissue concentrations 
  The effects of MDMA and WAY100635 pretreatment on 5-HT and 5-
HIAA brain tissue concentrations were determined by HPLC analysis 48 hours 
following behavioural testing. 
Results 
Effects of MDMA Pre-treatment on MDMA-induced hyperactivity   
Figure 21 shows the time course of MDMA-produced hyperactivity in 
saline and MDMA pretreated rats (Figure 21A). A 3-Way-ANOVA (time X dose 
X pretreatment) with time as a repeated measure revealed no significant 
interaction between these factors (F(11, 286)=.471, p>.05). There was a main 
effect of pretreatment (F(1,26)=7.145, p<.05) with MDMA pretreated rats 
showing reduced MDMA produced hyperactivity. Figure 21B shows the total 
activity counts in the 60minute period post an acute MDMA (0.0, 10.0mg/kg) in 
saline and MDMA pre-treated rats. A 2-Way ANOVA (MDMA dose X MDMA 
pretreatment) revealed an interaction (F(1,20) = 5.53, p<0.05) with a main effect 
of MDMA dose (F(1,20) = 125.05, p <0.01) and pre-treatment (F(1,20) = 5.48, p< 
0.05). MDMA pretreatment attenuated MDMA-induced hyperactivity indicating 
tolerance. 
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Figure 21 Activity counts produced following MDMA (0.00, 10.0 mg/kg, IP) 
administration in MDMA pretreated rats. The top panel (Figure 21A) shows 
the time course of the mean activity counts produced by MDMA (0.0, 
10.0mg/kg, IP at time =0) administration following saline or MDMA 
pretreatment (+SEM) while the bottom panel (Figure 21B) shows the total 
activity counts produced in the 60 minute period post MDMA (0.0, 10.0mg/kg, 
IP) in saline and MDMA pretreated. Significant difference relative to 
MDMA pretreatment group * p<.05. 
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Effects of WAY100635 on MDMA-produced hyperactivity following MDMA 
pretreatment  
Figure 22 shows the time course of MDMA produced locomotor activity 
in the 60 min period after an acute MDMA (0.00, 10.0mg/kg) injection in saline 
(Figure 22A) and MDMA pre-treated (Figure 22B) rats that received 
WAY100635 (0.00, 500ng, IC) administration. A 4-Way ANOVA (time X 
MDMA pretreat X WAY100635 X MDMA dose) with time as a repeated measure 
revealed no interaction between these factors (F(11,451)=.52, p>.05) nor between 
MDMA pretreatment, WAY pretreatment and MDMA dose (F(1,41)=2.71, p>.05) 
and MDMA pretreatment and WAY pretreatment (F(1,41)=3.15, p>.05). There 
were interactions between MDMA pretreatment and MDMA dose 
((F(1,41)=19.10, p<.05) and WAY pretreatment and MDMA dose (F(1,41)=9.30, 
p<.05). A 2-Way ANOVA (time X WAY pretreat) with time as a repeated 
measure in saline pretreated rats revealed an interaction between these factors 
(F(11,110)=2.09, p<.05) and a main effect of WAY pretreatment (F(1,10)=30.66, 
p<.05). In saline pretreated rats WAY100635 pretreatment significantly 
potentiated MDMA-induced hyperactivity. A 2-Way ANOVA (time X WAY 
pretreat) with time as a repeated measure in MDMA pretreated rats revealed no 
interaction between these factors (F(11,121)=1.68, p>.05) and no main effect of 
WAY pretreatment (F(1,11)=1.00, p>.05). In MDMA pretreated rats 
WAY100635 pretreatment did not alter MDMA-induced hyperactivity. 
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Figure 22 The time course of activity counts in saline (Figure 22A) and 
MDMA pretreated (Figure 22B) rats produced in the 60minute period post 
an acute MDMA(0.0, 10.0mg/kg, IP) administration following 4 day 
WAY100635 (0.0, 500ng, IC) microinjections. 
 
Figure 23 shows the total activity counts in the 60minute period post an 
acute MDMA (0.0, 10.0mg/kg) in saline (Figure 23A) and MDMA pretreated 
(Figure 23B) rats following a 4 day WAY100635 (0.0, 500ng, IC) administration. 
A 3-Way ANOVA (MDMA Pretreat X WAY100635 Pretreat X MDMA Dose) 
  
92 
revealed no interaction between these factors (F(1,41)= 2.69, p> .05) nor between 
MDMA pretreatment and WAY100635 pretreatment (F(1,41)=3.39, p>.05).There 
were interactions between MDMA pretreatment and MDMA dose (F(1,41)=18.74, 
p<.05) and WAY100635 pretreatment and MDMA dose (F(1,41)=8.78, p<.05). 
Additionally, there was a main effect of MDMA pretreatment (F(1,41)=20.44, 
p<.05), WAY100635 pretreatment (F(1,41)= 13.67, p< .05) and MDMA dose 
(F(1,41)= 248.27, p<.05). 1-Way ANOVAs revealed a main effect of 
WAY100635 pretreatment on MDMA-produced hyperactivity in saline pretreated 
rats (F(1,10)=32.05, p<.05) but not in MDMA pretreated rats (F(1,11)=.95, p>.05). 
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Figure 23 Total activity counts in saline (Figure 23A) and MDMA pre-
treated (Figure 23B) rats produced in the 60minute period post an acute 
MDMA(0.0, 10.0mg/kg, IP) administration following 4 day WAY100635 (0.0, 
500ng, IC) microinjections. Significance relative to MDMA pretreatment 
group * p<.05. 
 
Observations 
Following the 60min period recorded in the activity chambers, animals 
were returned to their home cages. Informal observation of the MDMA pretreated 
animals following WAY100635 pretreatment was that these rats remained 
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hyperactive for a prolonged period following acute MDMA administration. Some 
of these animals were extremely active. Stereotypic behaviour was also evident.  
 
Effect of MDMA and WAY100635 Pretreatment on brain 5-HT and 5-HIAA 
tissue concentration. 
Figure 24 shows a diagrammatic representation of coronal sections 
through the rat brain showing the location of correct injection sites (black circles) 
inside the DRN. Figures represent coordinates from Paxinos and Watson (2005) 
rat brain atlas.  
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Figure 24 Diagrammatic representations of coronal sections through the rat 
brain showing the location of correct injection sites (black circles) inside the 
DRN. Figures represent coordinates from Paxinos and Watson (2005) rat 
brain atlas, with respect to bregma. Aq: aquaduct; Cb: cerebellum; DMTg: 
dorsomedial tegmental area; DR: dorsal raphe nucleus; 4V: fourth ventricle; 
MnR: medial nucleus raphe; PAG: periaqueductal gray; PMnR: 
paramedical raphe.  
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Table 4 show the effect of MDMA pre-treatment and WAY100635 
administration on brain 5-HT and 5-HIAA tissue levels. In the frontal cortex 2-
Way ANOVA’s (MDMA Pretreatment X WAY100635) on 5-HT and 5-HIAA 
tissue levels revealed no interactions between these factors (F(1,19)=.005, p>.05) 
and (F(1,19)=.455, p>.05) respectively (Table 4). There was a main effect of 
MDMA pretreatment on 5-HT (F(1,19)=6.116, p<.05) and 5-HIAA 
(F(1,19)=21.088, p<.05) levels indicating that MDMA pretreatment significantly 
reduced 5-HT and 5-HIAA brain tissue levels. There was also a main effect of 
WAY100635 pretreatment on 5-HT (F(1,19)= 6.493, p<.05) and 5-HIAA 
(F(1,19)=4.345, p<.05) indicating that in both MDMA and saline pretreated 
animals WAY100635 increased frontal cortex 5-HT and 5-HIAA tissue levels 
(Table 4).  
In the striatum 2-Way ANOVA’s (MDMA Pretreatment X WAY100635 ) 
on 5-HT and 5-HIAA tissue levels revealed no interactions between these factors 
(F(1,19)=.429, p>.05) and (F(1,19)=.925, p>.05) respectively (Table 4). There 
was a main effect of MDMA pretreatment on 5-HT (F(1,19)=6.431, p<.05) and 5-
HIAA (F(1,19)=20.220, p<.05) levels indicating that MDMA pretreatment 
significantly reduced 5-HT and 5-HIAA brain tissue levels. There was also a main 
effect of WAY100635 pretreatment on 5-HT (F(1,19)= 8.650, p<.05) however 5-
HIAA (F(1,19)=1.122, p<.05) levels failed to reach significance. Therefore, in 
MDMA and saline pretreated animals WAY100635 increased 5-HT tissue levels 
in both brain regions while only increasing 5-HIAA levels in the frontal cortex 
(Table 4).  
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Table 4 HPLC analysis of frontal cortex and striatal 5-HT and 5-HIAA tissue 
levels (ng/mg) following MDMA and WAY100635 pretreatment, (a) p<.05 
compared to SSS group: (b) p<.05, compared to the relative saline or MDMA 
control group.  
5-HT and 5-HIAA Tissue Levels (ng/mg) 
Frontal Cortex Striatum 
 
5-HT 5-HIAA 5-HT 5-HIAA 
SSS .320±.03 .460±.04 .270±.03 .710±.06 
SWS .490±.07b .490±.07 .460±.06b .660±.06 
MSS .210±.02a .210±.02a .160±.01a .390±.03a  
MWS .320±.06
 b .320±.06 b .290±.08b .400±.05 
 
. 
 
 
Discussion 
In the present study MDMA produced a dose dependent increase in 
locomotor activity. This hyperactivity was attenuated by MDMA pretreatment, 
suggesting tolerance. As previously reported this behavioural tolerance was 
accompanied by MDMA-induced reductions in 5-HT and 5-HIAA levels in the 
striatum and frontal cortex (Shankaran & Gudelsky, 1999). 
In line with other studies there was no change in baseline locomotor 
activity following MDMA pretreatment (Bull et al., 2003; McNamara, Kelly, & 
Leonard, 1995). This suggests that any deficits produced by MDMA pretreatment 
are not functionally evident under baseline conditions and require a 
pharmacological challenge to be observed. Additionally, no change in baseline 
activity was evident following the chronic 4 day intracranial administration of the 
5-HT1a antagonist, WAY100635. This is consistent with previous findings 
showing that lesions of the DRN did not alter spontaneous activity in rats (Geyer, 
Puerto, Menkes, Segal, & Mandell, 1976; Jacobs, Wise, & Taylor, 1974).  
There are several major findings in this study related to the chronic 
administration of WAY100635. In saline pretreated rats WAY100635 
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pretreatment potentiated MDMA-produced hyperactivity. This was accompanied 
by an increase in 5-HT and 5-HIAA tissue levels in the striatum and frontal cortex. 
MDMA induces locomotor activity through the release of monoamines and the 
subsequent activation of 5-HT and DA receptor subtypes (Bankson & 
Cunningham, 2001; Green et al., 2003). The potentiation of activity in the current 
study may therefore be due to an increase in 5-HT availability as seen in the 
striatum and frontal cortex. As DRN 5-HT1a autoreceptor activation inhibits 5-HT 
synthesis in forebrain regions (Hillegaart, Hjorth, & Ahlenius, 1990) it is 
suggested that increases in 5-HT and 5-HIAA tissue levels in the present study 
may be attributed to blockade of the DRN 5-HT1a autoreceptors. 
A marked increase in MDMA-induced locomotor activity was also evident 
in MDMA pretreated animals but this effect failed to reach significance. This lack 
of effect may be partly due to small group numbers. There was high variability in 
MDMA pretreated rats with activity of one of the five animals 21% below the 
group mean. Alternatively, while the withdrawal period in the current experiments 
was extended compared to that in section 4, a longer period may be required in 
order for reversal effects, as seen in saline pretreated animals, to be evident.  
In MDMA pretreated animals WAY100635 administration produced an 
increase in 5-HT tissue concentrations in the frontal cortex and striatum. 5-HIAA 
levels were increased in the frontal cortex however the striatum was unaffected. 
This is in line with reports that MDMA-produced 5-HT depletions can be partially 
restored. Administration of the 5-HT precursor L-5-hydroxytryptophan (5-HTP) to 
MDMA pretreated rats partially restored 5-HT tissue levels 2 hours post 
administration (Wang et al., 2007). The lack of reversal of 5-HIAA in the striatum, 
as with the lack of effect on locomotor activity, suggests that MDMA 
pretreatment may render the 5-HT system less responsive to treatment. In line 
with the hypothesis of a supersensitive autoreceptor following MDMA 
pretreatment, this suggests that the efficacy 5-HT1a autoreceptor to negatively 
control 5-HT transmission is enhanced following MDMA pre-exposure. It is 
possible that a longer period of autoreceptor blockade or possibly a higher dose of 
WAY100635 may produce effects similar to those seen in controls.  
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Future experiments may determine the efficacy of the 5-HT1a autoreceptor 
to inhibit 5-HT transmission through direct measurement of 5-HT synthesis. 
Biochemical experiments which examine the accumulation of 5-HTP (Kelai et al., 
2008) may further elucidate the functional status of the 5-HT1a autoreceptor 
following MDMA pretreatment and determine if the reversal of depletions as seen 
in the present study are due to a change in the functional status of the receptor by 
repeated receptor antagonism by WAY100635 and ultimately increased 5-HT 
synthesis. 
Decreases in DRN 5-HT1a autoreceptor binding have been reported 7 days 
following high dose MDMA exposure (Aguirre et al., 1995; Aguirre et al., 1997). 
However, altered functional responses have been reported with no change in 
receptor binding (Richtand et al., 2003; Shuto et al., 2008). As the 5-HT1a 
receptors are coupled to Gαi and Gαo proteins (Mannoury la Cour et al., 2001). 
Future studies examining the coupling efficacy of the receptors to the G protein 
may also help elucidate the mechanism by which MDMA has altered the 
functional status of the 5-HT1a autoreceptor.  
The mechanism responsible for the observation of a prolonged period of 
MDMA-produced hyperactivity in MDMA pretreated rats in the present study is 
not known. However, it is possible that the lack of a significant but marked 
increase in activity was due to an increase in other behaviours induced by MDMA 
and known to be 5-HT modulated. Stereotypic behaviour was evident when the 
animals were returned to their home cages. It is possible that a potentiated 
MDMA response could have resulted in behaviours associated with the 5-HT 
syndrome such as a flattening of the body resulting in impaired locomotor activity. 
Future studies may address this confound by administering various MDMA doses 
and measuring locomotor responses following WAY100635 administration.  
It remains controversial whether MDMA is neurotoxic to 5-HT terminals 
or produces neuroadaptations (Baumann et al., 2007). Given recent findings that 
MDMA produces no reactive gliosis (Baumann et al., 2007) that MDMA-induced 
5-HT depletions can be partially restored by administration of 5-HTP (Wang et al., 
2007) and, as in the current study, by blockade of the inhibitory DRN 5-HT1a 
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autoreceptor, support the idea that high dose MDMA produces a neuroadaptive 
response rather than neurotoxicity.  
The results in the present study suggest that blockade of the DRN 5-HT1a 
autoreceptor may offer an alternative mechanism to reverse the effects of repeated 
MDMA exposure and as a result may have a major implication for clinical use. 
The 5-HT1a autoreceptor may be a viable target for restoring 5-HT concentrations 
in abstinent MDMA users who display ongoing cognitive and psychological 
impairments due to 5-HT deficits. However, as shown by the reduced effect of 
WAY100635 treatment in MDMA pretreated animals, it is suggested that the 5-
HT system may be severely compromised following MDMA exposure and that 
future MDMA use may induce irreversible deficits. 
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General Discussion 
The aim of the current thesis was to investigate the role of the 5-HT2a, 5-
HT2c and 5-HT1a receptors in tolerance to the effects of MDMA following 
repeated MDMA exposure and to attempt to reverse tolerance through the local 
application of a 5-HT antagonist.  
In section 1 the Emergence Test (ET) was developed as a behavioural 
assay that provided a reliable, sensitive measure of the effects of MDMA. 
Furthermore, the ET was developed an assay responsive to specific 5-HT 
pharmacological probes in order to investigate the contribution of specific 5-HT 
receptors to the effects of acute and repeated MDMA exposure. Experimental 
parameters including habituation periods, handling procedures, test exposure 
effects as well as MDMA dose and time course effects were determined. To date 
the number of studies examining the effect on neotic preferences in rats, as seen in 
the ET, by 5-HT agonists such as MDMA has been limited and those described 
often reported conflicting results (Cox & Tye, 1975; Hughes & Pither, 1987; 
McGregor et al., 2003; Morley et al., 2005). Many of the discrepancies have been 
attributed to methodological procedures or animal species/strain. The present 
study adds to the literature by providing a procedure for examining the effects of 
both acute and repeated MDMA administration in the ET. Future research may 
now add the ET to the battery of assays utilised to investigate the effects of 
MDMA administration by applying the parameters indicated within these findings. 
Section 2 utilised the ET to investigate the contribution of the 5-HT2a and 
5-HT2c receptors to the acute and repeated effects of MDMA. Tolerance has been 
shown to be one of the most reported effects of MDMA use in humans leading to 
increases in MDMA dose and frequency of consumption (Parrott, 2005). However, 
few animal studies have examined the functional consequence of repeated 
MDMA exposure (Baumann et al., 2008; Shankaran & Gudelsky, 1999). 
Therefore, the present study adds to an area of research that is limited yet has 
major implications for humans who use and abuse MDMA. Three major findings 
resulted from Section 2. Previous studies have suggested that, following repeated 
MDMA exposure, tolerance to the effects of various 5-HT agonists was likely due 
to impaired 5-HT release (Baumann et al., 2008; Bull et al., 2003; Shankaran & 
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Gudelsky, 1999). While these findings elucidated the possible mechanisms 
underlying MDMA-induced tolerance it was not established whether this was 
relevant for MDMA produced effects. The present study was therefore the first to 
demonstrate tolerance to MDMA produced decreases in emergence latency in the 
Emergence Test. Secondly that the reduction in emergence latency was likely due 
to impaired 5-HT release. And thirdly, that the 5-HT2c receptors associated with 
exploratory behaviour may not become desensitised following MDMA pre-
treatment, as previously suggested (Bull et al., 2003). This suggests that any 
changes in the response of the 5-HT2c receptor following MDMA exposure may 
be secondary to alterations in 5-HT transmission. SERT-mediated 5-HT release 
has also previously been shown to be a predominant mechanism underlying the 
response to MDMA’s decreased ability of MDMA to enhance synaptic 5-HT 
(Schenk et al., 2007, Rudnick & Wall, 1992). However, given the significant 
depletions in 5-HT and 5-HIAA in the brain regions examined in the present study, 
impaired SERT-mediated 5-HT release was, as with possible inactivation of the 5-
HT2c receptors, likely to be secondary to impaired 5-HT synthesis. Therefore, 5-
HT synthesis rather than 5-HT reuptake was targeted via the 5-HT1a autoreceptor 
known to mediate 5-HT transmission. 
In section 3 the potentiated response to low dose 5-HT1a agonist, as 
measured by hypothermia, led to the hypothesis that following MDMA 
pretreatment the 5-HT1a autoreceptor was rendered supersensitive. It was 
suggested that this heightened sensitivity enhanced the autoreceptor’s inhibitory 
action on 5-HT release and synthesis and thereby contributed to tolerance. A 
supersensitivity of the 5-HT1a autoreceptor has also been reported in wild-type 
mice following MDMA exposure (Renoir et al., 2008) as shown by a higher 
potency of a selective 5-HT1a receptor agonist to inhibit cell discharge. Further, 
the hypothermic response in mice was enhanced following MDMA pre-treatment 
(Hedlund et al., 2004). In rats a 14 day pre-treatment with cocaine also resulted in 
5-HT1a autoreceptor supersensitivity (Cunningham et al., 1992), and chronic 
alcohol intake was found to induce the same effect in C57BL/6J mice (Kelai et al., 
2005). Within these studies a variety of dosing regimens, from single day high 
dose regimens to daily exposure over a number of days, have all produced a 
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supersensitivity of the 5-HT1a autoreceptor. However, varying MDMA pre-
treatment regimens have induced both increased and decreased responses to acute 
MDMA. An interesting question for future studies is whether the adaptive 
changes, as shown in the present study, occur under various MDMA dosing 
regimens. By administering a range of MDMA pre-treatment regimens that induce 
tolerance will help determine the parameters of MDMA exposure that elicit 5-
HT1a receptor supersensitivity and therefore the possibility that the 5-HT1a 
autoreceptor contributes to tolerance to MDMA-produced effects. 
Previous studies have attempted to block the effects of repeated MDMA 
exposure on the 5-HT system. However, only one other study has attempted to 
reverse the effects of repeated MDMA exposure. Administration of the 5-HT 
precursor 5-HTP potentiated an MDMA-induced effect (Wang et al., 2007). The 
present study aimed at inducing potentially longer lasting neuroadaptive changes 
rather than the transient effect reported (Wang et al., 2007). Therefore, a 5-HT1a 
antagonist was chronically administered in an attempt to desensitise the receptor 
reducing its inhibitory actions and reverse the tolerance to MDMA produced 
effects. These effects were observed 3 days following 5-HT1a antagonist pre-
treatment. Previous literature has shown some MDMA-induced behavioural 
deficits may persist up to 12 months (Battaglia et al., 1988) while others have 
shown recovery after 12 weeks (Brennan & Schenk, 2006). By examining various 
periods post pre-treatment the sustainability and therefore the therapeutic 
usefulness of the present reversal may be determined.  
Previous literature has shown that administration of a 5-HT1a agonist also 
desensitises the 5-HT1a receptor (Aguire et al., 1998). In contrast, the present 
study utilised the novel approach of administering a 5-HT antagonist pretreatment 
to desensitise the 5-HT1a autoreceptor. This approach was chosen as chronic 
application of the 5-HT1a antagonist WAY100635 had previously been shown to 
increase 5-HT synthesis in various brain regions including the DRN (Tohyama et 
al., 2001). Both of these approaches have the potential to modify and possibly 
reverse tolerance to MDMA effects following high dose MDMA. Future studies 
may therefore attempt to replicate the present findings following an agonist pre-
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treatment. A combination of these approaches may help elucidate any differential 
mechanisms that each of these approaches may utilise.   
One of the major findings of this thesis was a partial reversal of 
behavioural tolerance and complete reversal of the 5-HT deficits produced by 
MDMA pretreatment as a result of local DRN application of a 5-HT1a antagonist. 
While systemic application failed to produce any reversal, the results highlight the 
DRN 5-HT1a autoreceptor as a possible target for the development of 
pharmaceuticals relevant to MDMA use. While a potential therapeutic mechanism 
has been elucidated, local application inhibits its human application. Therefore, 
future studies examining various 5-HT1a antagonist doses and withdrawal times 
may allow systemic antagonist application to be successful. Additionally, future 
development of highly selective 5-HT1a autoreceptor agonists/antagonists may 
allow systemic rather than local application of the pre-treatment and therefore 
provide an approach to reducing the long term complications that arise from 
repeated human MDMA use. Further, the exact mechanism by which this 
approach was successful is yet to be determined. Future experiments such as 
biochemical experiments which examine the accumulation of the 5-HT precursor 
5-hydroxytryptophan (5-HTP) following MDMA exposure may help elucidate 
these mechanisms. 
Whether or not MDMA is neurotoxic to 5-HT nerve terminals remains 
controversial. Previous literature has examined a variety of end point measures of 
MDMA toxicity.  A lack of reactive gliosis (Baumann et al., 2007) and an ability 
to top up intact nerve terminals following 5-HTP administration (Wang et al., 
2007) would suggest a neuroadaptive response of the 5-HT system following 
MDMA rather than neurotoxicity. In the present study MDMA-induced depletions 
of 5-HT were reversed via the mechanism known to be responsible for 5-HT 
synthesis. Thus the present study supports a model of neuradaptation, as opposed 
to neurotoxicity, following repeated high dose MDMA administration on rat brain 
serotonergic systems.  
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